NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Epstein R, Fonnesbeck C, Williamson E, et al. Psychosocial and Pharmacologic Interventions for Disruptive Behavior in Children and Adolescents [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2015 Oct. (Comparative Effectiveness Reviews, No. 154.)
Psychosocial and Pharmacologic Interventions for Disruptive Behavior in Children and Adolescents [Internet].
Show detailsDescription of Included Studies
The PRISMA85 literature flow diagram (Figure 2) reports the number of records retrieved from indexed, published literature and the overall number of records (including unique studies and related publications) retained for all Key Questions (KQs) and the meta-analysis. From our search of the literature we screened 7470 records; we excluded 6502 based on the abstract and title. We retrieved the full text of 968 publications. Of these, 852 were excluded for one or more reasons. Appendix H includes a list of excluded publications and exclusion reasons.
We retained 115 publications, representing 84 unique studies to address one or more KQs in this review. For Key Question 1 (KQ1) we identified 89 publications representing 66 unique studies. For Key Question 2 (KQ2) we identified 15 publications representing 13 unique studies. We included the data from the 13 studies addressing KQ2 and identified an additional three studies for Key Question 5 (KQ5). We found no head-to-head studies assessing the effectiveness of psychosocial versus pharmacologic intervention (Key Question 3) or combined psychosocial and pharmacologic interventions (Key Question 4) for the treatment of disruptive behavior in children. We summarize information on moderators and mediators of intervention effectiveness for Key Question 6 (KQ6) from 23 studies that addressed KQ1 or KQ2. For each KQ, we present findings by intervention and outcome where possible.
Studies of psychosocial interventions (KQ1) were heterogeneous. We categorized studies based on the active study arm and identified psychosocial interventions including only a child component, interventions including only a parent component, or as multicomponent (i.e., two or more of a child, parent, or other type of intervention component) intervention. We identified a subset of studies (n =28) from KQ1 to contribute data to the network meta-analysis. These studies were RCTs that reported baseline and end of treatment outcomes for at least one intervention and control group (i.e., study arm) using one or more of the three most prevalent measures of disruptive behavior (described above).
Pharmacologic interventions (KQ2) included antipsychotics, antiepileptics, and two groups of drugs (stimulants and nonstimulants) typically used to treat attention deficit hyperactivity disorder (ADHD). We report harms of pharmacologic interventions from 16 studies (reported in 18 papers). To augment the empirical data, we briefly summarized data from the gray literature (i.e., package inserts and FDA reviews) and prior systematic reviews (n = 3) that reported harms associated with the drugs that were included in the literature we assessed for KQ2. We compared the information obtained from the literature and regulatory sources with the Scientific Information Packets to confirm that we identified all relevant reports of harms data.
We present information reported in 37 publications (representing 23 studies) in KQ6 by patient characteristics (KQ6a), intervention characteristics (KQ6b), treatment history (KQ6c) and treatment characteristics (KQ6d).
Key Question 1. In children under 18 years of age treated for disruptive behaviors, are any psychosocial interventions more effective for improving short-term and long-term psychosocial outcomes than no treatment or other psychosocial interventions?
Overview of the Literature for KQ1
This section presents results of studies meeting our review criteria and addressing the effectiveness of psychosocial treatments for disruptive behavior. Sixty-six studies (reported in 89 papers) of psychosocial intervention met the criteria for inclusion. Of the 66 included studies, 59 were randomized controlled trials (RCTs) (6031 was the total number of patients randomized for all studies in this section) and seven were nonrandomized controlled studies (including 1144 participants).86-92 About half of the studies (n = 25) were conducted in the United States;93-116 the remaining studies were conducted in: Australia (n = 11); Canada (n = 4); Germany (n = 3); Ireland (n = 2); Israel (n = 2); Netherlands (n = 5); Norway (n = 4); Puerto Rico (n = 1); Sweden (n = 3); and the United Kingdom (n = 5).117-147 For the qualitative synthesis, we group studies by active psychosocial intervention arm as interventions including only a child component, interventions including only a parent component, or as multicomponent interventions (Table 5). We defined a multicomponent intervention as one that included two or more of a child component, parent component, or other component (e.g., teacher component, family together component).
We report the findings first by age group (preschool age, school age, and teenage) and then by intervention, grouping first by components (e.g., child only, parent only, multicomponent) and then within components by specific interventions. We summarize the group difference in parent reported child disruptive behaviors reported by the Eyberg Child Behavior Inventory (ECBI) Intensity scale, ECBI Problem scale, or Child Behavior Checklist (CBCL) Externalizing scale T-score from baseline to the last followup in tables within each age group.
The most commonly included named intervention was the Incredible Years (IY) program (12 studies). The IY program is a therapist-led, videotape modeling discussion program. The IY program includes child (IY-CT), parent (IY-PT), and teacher training (IY-TT) programs, which may be delivered individually or in combination with each other. The IY-PT program, for example, trains parents general ways of interacting and communicating with children and operant techniques for handling behavior problems.148
The next most commonly included named intervention was Parent Child Interaction Therapy (PCIT) (7 studies). PCIT is used primarily with young children with emotional and behavioral disorders emphasizes the quality of the parent-child relationship and parent-child interaction patterns.149
The third most commonly included named interventions (5 studies each) were the Positive Parenting Program (Triple P) and Multisystemic Therapy (MST). Triple P provides parenting and family support to prevent and treat behavioral and emotional problems in children and teenagers. The program uses a multilevel approach and draws on social learning, cognitive behavioral and developmental theory to teach parenting strategies to develop positive relationships, attitudes and conduct.150 Multisystemic Therapy (MST) is family-based treatment approach for improving the antisocial behavior. MST is conducted in the youth's home, school, or community. The focus of MST is to teach parents how to be more effective at managing their child's activities and develop positive support systems.151
Brief Strategies Family Therapy (BSFT) was the active intervention in three included studies. BSFT is a short-term office-based model focused on the family to reduce mild to moderate behavior problems in adolescents.152
The 34 remaining included studies did not include more than two studies of any other named intervention. Interventions such as Parent Management Training Oregon Model (PMTO), the Coping Power Program, Helping the Noncompliant Child, and the Stop Now and Plan Under 12 Outreach Project (SNAP Under 12) program are representative examples.
Following the qualitative summary of the literature for KQ1, we report the findings from a Bayesian multivariate, mixed treatment (network) meta-analysis of a subset of the KQ1 literature (28 of 66 studies) that met criteria for inclusion in this analysis (as described in Methods above). For the network meta-analysis, we classified the active psychosocial intervention arm, active treatment comparison arms (if applicable), and control arms as interventions including only a child component, interventions including only a parent component, multicomponent interventions (as defined above), or as a control arm (also as defined above).
Key Points for KQ1
Preschool Children
- A majority (17 of 23) of studies of psychosocial interventions for preschool-age children with disruptive behaviors assessed one of three programs: IY (n = 5); PCIT (n = 7); and Triple P (n = 5). The six other studies assessed each assessed a different intervention.
- We categorized 14 studies as examining an intervention with an active treatment arm with only a parent component and nine studies as examining multicomponent interventions. There were no studies in this age group examining an intervention with only a child component as the active treatment.
- In three of five studies assessing only the parent-training component of the IY intervention, outcomes on the ECBI and CBCL were significantly improved in the treatment versus control arms. Outcomes did not differ between groups in two studies.
- In all five studies assessing the Triple P intervention, outcomes on the ECBI were significantly improved in the treatment compared with the control arms.
- In all seven studies assessing PCIT, problem behavior outcomes were significantly improved in the treatment group compared with the control arms. In the two studies comparing adapted versions of PCIT, differences in effects of PCIT versions were not significant.
School-Age Children
- Of the studies that assessed psychosocial interventions for school-age children with disruptive behaviors, the active treatment arm was categorized as including only a child component in 1 study, 11 studies as only a parent component, and 17 studies as multicomponent.
- Five of the 11 interventions identified as including only a parent component examined the parent training program of the IY-PT intervention (n = 3) or PMTO (n = 2). The six other studies each assessed a different intervention.
- Studies assessing IY-PT or PMTO interventions consistently reported greater improvements in child disruptive behaviors in the treatment versus control arms.
- A majority (10 of 17) of the studies examining multicomponent interventions assessed more than one of the IY intervention components delivered together (n = 4), the Coping Power Program (n = 2), a modular intervention (n = 2), or SNAP Under 12 ORP (n = 2). The seven other studies each assessed a different intervention.
- The IY and SNAP Under 12 ORP interventions consistently resulted in greater improvements in child disruptive behaviors than controls.
Teenage Children
- Of the studies that assessed psychosocial interventions for teenagers with disruptive behaviors, the active treatment arm of one study was categorized as including only a child component and of 13 studies to assess multicomponent interventions.
- A majority (8 of 14) of the studies examined one of two interventions: MST (n = 5) and BSFT (n = 3).
- Four of the five studies assessing MST reported significantly greater reductions in child disruptive behaviors for the treatment versus control arms.
- Each of the three studies assessing BSFT reported significantly greater reductions in child disruptive behavior compared with the control arms.
Meta-Analysis
- Results from our Bayesian multivariate, mixed treatment (network) meta-analysis indicated that the probability of having the largest effect was the same for multicomponent interventions (43%) and interventions with only a parent component (43%) , followed by interventions with only a child component (14%). All interventions categorized as multicomponent interventions included a parent component and at least one of a child, teacher, family together, or other component. Each of these intervention categories was associated with better outcomes than control arms.
Preschool Children
Description of Included Studies
We identified 23 studies87,93,95,98,99,102,107,109,112,114,119,127,129,133,135,138-141,145,153-155 represented in 31 publications87,93,95,98,99,102,107,109,112,119,127,129,133,135,138-141,145,153-163 that examined psychosocial interventions for preschool-age children with disruptive behaviors. Of the 23 included studies, 22 were RCTs (10 high, 10 moderate, and 2 low risk of bias)93,95,98,99,102,107,109,112,114,119,127,133,135,138-141,145,153-155,158 and one was a prospective nonrandomized controlled study (moderate risk of bias).87 Studies were conducted in the United States (n = 9)93,95,98,99,102,107,109,112,114 and Australia (n = 9).133,135,140,141,145,153-155,164 We identified a single study conducted in one of each country: Canada,127 Ireland,138 Israel,119 the Netherlands,87 and the United Kingdom.129 Fourteen of the 23 included studies evaluated interventions including only a parent-component (Table 6). Nine of the 23 included studies evaluated multicomponent interventions. Each type of intervention is discussed separately below.
Detailed Analysis
Interventions With Only a Parent Component
Of the 14 studies evaluating interventions with only a parent component for preschool-age children with disruptive behaviors, we identified five studies87,93,102,129,138 (reported in 8 publications)87,93,102,129,138,158,159,163 that examined the Incredible Years– Parent Training (IY-PT) program. We identified five studies of Triple P,135,139-141,145 and four RCTs that examined other interventions including only a parent component.95,119,127,155
Incredible Years – Parent Training (IY-PT)
Four RCTs (1 high, 2 moderate, and 1 low risk of bias)93,102,129,138 and one prospective cohort study (moderate risk of bias)87 evaluated a version of the IY-PT (Table 7). Of these, two RCTs129,138 and the prospective cohort study87 evaluated the standard version of the IY-PT, one RCT93 evaluated a brief version of the IY-PT, and one RCT (reported in 2 publications)102,159 evaluated a nurse-led or therapist-led version of the IY-PT.
All three of the studies evaluating the IY-PT standard version measured child disruptive behaviors using the ECBI Problem scale.87,129,138,163 Two of these studies also used the ECBI Intensity scale and Dyadic Parent-Child Interaction Coding System-Revised (DPICS-R) as additional measures of child disruptive behaviors.87,138 One study used the Strengths and Difficulties Questionnaire (SDQ)138 and one used the CBCL.102,159 Comparison groups included usual care (n = 1),87 waitlist control group (n = 3),93,129,138 and a group led by a different provider or receiving no interventionist-led training (1 study reported in 2 publications).102,159 Timing of the final followup ranged from 3 months to 2 years post-intervention across studies. Table 7 summarizes key outcomes. Briefly, in three of the five studies, the groups receiving IY intervention had significantly improved behavioral outcomes compared with control arms. In one study comparing differing administration of the IY intervention and in comparing IY to usual care, ECBI outcomes did not differ significantly among groups.
The moderate risk of bias prospective cohort study87 compared outcomes in 4-year old children [mean age: 4.2 (3.11)] scoring at or above the 80th percentile on the aggressive behavior scale of the CBCL to outcomes in children receiving usual care. Parents of children [n = 72, mean age: 50.3 (3.11) months, mean CBCL aggressive behavior raw score: 21.99 (4.37)] in the intervention group received 18 2-hour IY sessions (BASIC and ADVANCE) focusing on identifying strategies for dealing with child behaviors. Children in the control group [n = 72, mean age: 51.3 (2.53) months, CBCL aggressive behavior mean raw score: 22.49 (4.69)] received usual care. Groups differed significantly at baseline on age (control group 2 months older than intervention group, p=0.02), observed use of critical statements by parents (intervention group parents more critical than control, p=0.05), and observed conduct problems (more conduct problem in intervention group vs. control, p=0.004). Children did not differ at baseline on parent-rated measures. At final followup (2 years post-intervention), groups did not differ significantly on the ECBI. In observer coding (DPICS-R) of interactions, parents in the intervention group used significantly fewer critical statements than in the control group, and conduct problems decreased significantly in the intervention group compared with the control arm.
One RCT (reported in 2 publications)129,158 compared an IY intervention delivered by center staff in social service centers for economically disadvantaged children in the United Kingdom with a waitlist control group. Children included in the study were seen at the centers and had ECBI Intensity scores of 127 or greater or problem scores of 11 or greater, and most had low socioeconomic status. Eighty-six of the 104 children randomized to the IY group [mean age: 46.4 (6.6) months] and 45 of the 47 randomized to the waitlist control group [mean age: 46.2 (4.2) months] completed the followup assessments at 6 months post-treatment. In intention-to-treat analyses, the outcomes on both ECBI scales (intensity scale effect size: 0.89, 95% CI: 0.54 to 1.24; problem scale effect size: 0.63, 95% CI: 0.28 to 0.98) and on the SDQ conduct problems (effect size: 0.33, 95% CI: −0.02 to 0.68) scale were significantly improved (p values <0.05) in the IY group compared with controls. Instances of deviant child behavior coded in observations were lower in the IY group but group but group differences were not significant (effect size: 0.21; 95% CI: −0.13 to 0.55). Scores on hyperactivity scales (Conners, SDQ) were also significantly lower in the IY group compared with control (p values <0.05), while scores on the SDQ overall deviance scale did not differ significantly between groups.
Another trial conducted in Irish community service centers enrolled 149 children between the ages of 32 and 88 months who were referred to health services organizations for problem behaviors and who scored above the clinical cut offs (127 for Intensity and 11 for problem scale) on a parent-rated ECBI.138,163 The IY intervention was delivered by center staff. Ninety-five of the 103 children randomized to the IY group and 42 of 45 in the waitlist control group completed followup final assessments approximately 3 months after the end of treatment. In intention-to-treat analyses, the IY group improved significantly on both ECBI scales (p values <0.001) compared with the control arm (ECBI Intensity effect size: 0.70; 95% CI: 0.4 to 1.1; ECBI Problem subscale effect size: 0.75; 95% CI: 0.4 to 1.1). Scores on measures of hyperactivity, prosocial behavior, and emotional well-being were also significantly improved in the IY arm compared with control (p values <0.01). Child problem behaviors coded in observations also decreased significantly in the IY arm versus the control arm (effect size: 1.07, 95% CI: 0.6 to 1.6), but observations of positive child behavior did not differ significantly between groups. Investigators conducted observations with a subset of children in both groups. Intention-to-treat analyses of the children originally randomized to the IY-PT group at 12-month post-treatment followup assessment demonstrated that treatment effects were maintained from 6-month followup (e.g., end of treatment) to 12-month followup, although effect sizes were nominally – but not statistically significantly – smaller.163
A moderate risk of bias RCT93 compared outcomes in three groups: an intervention group randomly allocated to 10 weeks of IY parent training [n = 89, mean age: 2.8 (0.61) years]; a non-randomly allocated group receiving the 10-week training [n = 123, mean age: 2.90 (0.63) years]; and a randomly allocated waitlist control group [n = 61, mean age: 2.7 (0.55) years].93 All children had Infant-Toddler Social Emotional Assessment Scale scores at or above the 80th percentile. Groups were similar at baseline; however, families in the non-random IY group included more minorities and were more likely to report lower socioeconomic status. Mean baseline T-scores on the ECBI Problem subscale ranged from 60.1 to 62.8 and from 58.3 to 59.2 on the ECBI Intensity scale. At the 12-month followup, outcomes on the ECBI Problem and Intensity subscales and the Parenting Scale were significantly improved in both the IY arms compared with the control group (p<0.05). Mean decreases in negative parenting, child disruptive behaviors, and negative parent-child interaction coded on the DPICS-R were greater in the IY groups compared with the control group and did not differ significantly between the IY groups.
Another high risk of bias RCT evaluated outcomes following 6 to 12-week IY programs led by primary care nurses (n = 49 children) or by psychologists (n = 37 children) and among a group of children whose parents received the Incredible Years book but no specific interventionist-led training (n = 31 children).102,159 While the study enrolled 117 children, only 91 completed all assessments (77%). All children were between the ages of 3 and 6.11 years, and all had scores above the 90th percentile on the CBCL Externalizing scale and DSM-IV diagnoses of Oppositional Defiant Disorder (ODD). The mean baseline CBCL Externalizing score (SD) across groups was 70.7 (5.96) and mean ECBI Intensity score (SD) was 155.44 (27.41). Groups did not differ demographically or in comorbidities (27.4% with concomitant ADHD). At 12-months post-intervention, groups did not differ significantly on any ECBI or CBCL scale, though all groups improved from baseline. Scores on the ECBI were in the normal range for 23.1 percent of children across groups at followup and were in the normal range for 47.9 percent of children on the CBCL Externalizing scale. In equivalence testing, the combined interventionist-led groups and book-only group were equivalent at the 10 percent level (differing by <10% at post-treatment and the 12-month followup) on both scales, as were the nurse-led and psychologist-led groups. In dose-effect analyses, effects on both scales improved with increasing training sessions attended.
Positive Parenting Program (Triple P)
Five RCTs (2 high and 3 moderate risk of bias) evaluated a version of Triple P.135,139-141,145 Two studies evaluated a self-directed version,139,141 two studies evaluated an enhanced version,135,140 and one study evaluated an online version (Table 8).145 All RCTs of Triple P that met criteria for inclusion in this review were conducted in Australia, two in rural populations.
All five studies measured child disruptive behaviors with the ECBI Intensity and Problem subscales. Four of the five studies also used the Parent Daily Report (PDR),135,139-141 one study also used the SDQ,145 and only one study measured one of our protocol-defined functional outcomes.140 The only study to use direct observation145 did not use this measure for all participants. Total comparison groups included waitlist control groups (n = 4) and usual care or self-directed treatment (n = 2). The duration of treatment ranged from 8 to 11 weekly sessions. Timing of last followup was 4 months post-intervention in one study,141 6 months post-intervention in three studies135,139,145 and 1 and 3 years post-intervention in one.140,160,162 Table 8 summarizes key outcomes. Overall, ECBI outcomes and mean number of problem behaviors were improved in treatment arms compared with control.
One RCT comparing a 10-week, self-directed iteration of Triple P implemented by parents in rural areas of Australia to a waitlist control group reported improvements in behavioral outcomes in the intervention group [n = 12, mean age: 49.33 (14.05) months] compared with control [n = 11, mean age: 53.18 (11.26) months].141 Children were initially identified based on parent concern and interest in the study. Parents completed a DSM-IV diagnostic interview by phone to evaluate for the presence of ADHD (present in 5 intervention and 7 waitlist children), ODD (present in 8 intervention and 6 waitlist children), or conduct disorder (present in 1 treatment and 2 waitlist children). Intervention group parents received printed books and workbooks to work through each week and participated in weekly calls (mean duration of 20 minutes; range: 5 to 30 minutes) with a trained therapist to encourage problem-solving skills. At the end of the 10-week intervention, ECBI scores as rated by mothers and fathers were significantly improved in the intervention group compared with the control (p=0.0005). Mothers, but not fathers, also rated the number of problem behaviors as significantly improved (p=0.016) in the intervention group compared with control. At post-treatment 33 percent of children in the intervention arm remained above the clinical cut-off (ECBI score=127) for disruptive behavior, compared with 100 percent remaining in the clinical range in the control arm. At followup of seven of 12 intervention groups 4 months after the end of intervention, post-treatment effects were maintained except for an increase in child problem behaviors that remained lower than the mean baseline level. At followup, three of seven children (43%) remained in the clinical range for disruptive behavior on the ECBI.
Another RCT in a rural population compared a similar self-directed version of Triple P plus weekly phone conferences [n = 14, mean age: 47.21 (10.19) months] with self-directed Triple P alone [n = 15, mean age: 47.27 (9.84) months] and with a waitlist control arm [n = 12, mean age: 46.17 (13.29) months].135 Children had to have an ECBI Intensity score of ≥127 or problem score of ≥ 11 at baseline and parental concern about disruptive behavior. ECBI Problem and Intensity subscale scores and mean number of problem behaviors as rated by mothers were significantly improved in the treatment groups versus control, with significantly greater improvements in the self-directed plus phone arm compared with either other arm (all p values <0.01). Father-rated measures were not significantly different among groups. At followup 6 months after the end of treatment, effects were maintained for the intervention plus phone group and the intervention alone group, with continuing mother-reported improvements in the level of disruptive behaviors in the latter group. Almost 70 percent (69%, n = 9) of the intervention plus phone group and 57 percent (n = 8) of the intervention alone group showed reliable change on the ECBI Intensity scale at the 6-month followup.
Another RCT of self-directed Triple P [n = 32 at baseline, mean age: 42.91 (9.16) months] compared with a waitlist condition [n = 31 at baseline, mean age: 43.26 (9.10) months] reported similarly improved outcomes after the 10-week intervention in the treatment arm.139 Children had to have ECBI Intensity scores of ≥127 or problem score of ≥11 at baseline and parental concern about disruptive behavior. Scores on the ECBI Intensity and problem scales and the mean number of problem behaviors reported by parents were significantly improved in the treatment group (n = 21 at analysis) compared with control (n = 22 at analysis) at post-treatment (all p values <0.01; significance maintained in intention-to-treat analyses). At followup of 13 children in the intervention group 6 months after the end of treatment, improvements in child behavior were maintained, and 23 percent of children (3/13) showed clinically reliable behavioral improvements.
One RCT (reported in multiple publications) evaluated three variations of Triple P in 3-year old children compared with a waitlist control group (n = 77): self-directed alone (n = 75); self-directed plus 10 hours of therapist-led skills training with observation and feedback (n = 77); and self-directed plus 14 hours of skills training that included training in partner support and observation and feedback (n = 76).140,160,162 Families included in the study had at least one indicator of “family adversity,” which included maternal depression, low socioeconomic status or low occupational prestige, relationship conflict, or single parent family, and all children [mean age: 3.4 (3.66)] scored in the clinical range on the ECBI Intensity (≥127) or problem (≥11) scales. Attrition over the course of the intervention was significant, with 30 percent (66/228) not completing either the post-intervention or 1-year followup assessments. Analyses of attrition indicated that negative affect ratings were higher among parents who did not complete the intervention and that mothers who did not complete the intervention were more likely to rate child behavior negatively. At followup after 15 weeks of intervention, children in the Triple P plus 14-hour training condition had improved outcomes on the ECBI compared with children in the waitlist or self-directed alone conditions. Fathers of children in either of the conditions that included additional training reported fewer behavior problems compared with fathers of children in the waitlist arm. Fewer negative child behaviors were recorded in observations in both the additional training arms compared with the waitlist control (p values <0.05) in the 14-hour training arm compared with the self-directed arm (p<0.05). At the 12-month post-treatment followup, improvements in child behavior were maintained in the arms with additional training, but differences were not significant. Forty children in the 14-hour training arm, 56 in the 10-hour training arm, 32 in the self-directed only arm, and 21 in the waitlist arm had moved from the clinical range for disruptive behavior to the typical range on the ECBI (differences between all treatment groups and waitlist group significant at p<0.01; differences between the 14-hour and self-directed group significant at p<0.05; differences between the 10-hour arm and self-directed and 14-hour and 10-hour arm not significant). In a followup of 139 participants 3 years after the end of intervention,160 children continued to improve on measures of problem behavior from baseline but differences among groups were not significant, nor were the numbers of children who met diagnostic criteria for disruptive behavior disorders (range 23.4 to 32% with DBD diagnoses across treatment groups). Teacher ratings of behavior problems also did not differ among groups, and all ratings were in the non-clinical range.
A sub-analysis of 87 children with ADHD included in this RCT162 assigned to the 14-hour training arm (n = 26), the 10-hour arm (n = 29), or the waiting list (n = 32) had similar outcomes to those in the larger group, with significantly improved behaviors rated on the ECBI in children in the treatment arms compared with control at post-intervention. The mean number of problem behaviors was similarly lower in the treatment arms (all p values <0.05), and differences between the two treatment arms were not significant. Effects were maintained at the 1-year followup with no significant differences between treatment arms. At least 60 percent of children in each treatment arm met criteria for reliable change on the ECBI (p=NS) at the 1-year followup.
Finally, one RCT compared an online version of Triple P (n = 60) with internet use as usual (n = 56) among parents of children ages 2 to 9 [mean: 4.7 (1.76)] years with elevated ECBI scores.145 As in the other studies of Triple P, problem behaviors on the ECBI were significantly reduced in the intervention group compared with control at the 6-month followup (ECBI Problem subscale effect size: 0.60; ECBI Intensity subscale effect size: 0.74). Overall SDQ ratings were not significantly different between groups, nor were observed child disruptive behaviors (effect size: 0.14). At least 60 percent of children in the treatment arms were considered clinically improved on the ECBI Problem (60%, n = 34/57) and Intensity subscales (65%, n = 34/52) at the post-treatment assessment compared with 29 (n = 14/49) and 17 (n = 8/46) percent in the control group (p=0.001).
Other Interventions With Only a Parent Component
Four RCTs conducted in the United States (high risk of bias),95 Canada (high risk of bias),127 Israel (moderate risk of bias),119 and Australia (moderate risk of bias)155 examined other interventions including only a parent component (Table 9).95,119,127,155 All interventions targeted parent behaviors related to communication and discipline. One study incorporated technology to enhance the Helping the Noncompliant Child intervention,95 one adapted parent-training modalities,119 one evaluated Supportive Expressive Therapy-Parent Child model,127 and one randomized children to group program for parents called Tuning into Kids (TIK).155 Comparison groups included IY parent training, minimal intervention, standard, non-enhanced care, and treatment as usual. The final followup occurred at 6 months in one study,15512 months after the end of intervention in two studies,119,127 and was not clearly reported in one.95
One RCT compared the standard, clinic-based Helping the Noncompliant Child program [n = 8, mean age: 5.75 (2.12) years], which emphasizes parental attention and positive parent-child communication and relationships, with a technology-enhanced version [n = 7, mean age: 5.57 (1.27) years] that included the standard clinic-based training plus smartphones to watch video training, complete skill surveys, and to record interactions for feedback.95 Both groups were lower income and had ECBI scores in the clinical range (127 on the intensity scale or 11 on the problem scale), with higher intensity scores in the enhanced intervention group compared with standard intervention [148.86 (22.51) vs. 131.5 (2.87), p=NR]. At the end of intervention (timing of followup after the 8-10 intervention sessions per group not clear), scores on the ECBI Intensity and Problem scales favored the enhanced group versus the standard intervention group with between-group effect sizes of 0.99 (95% CI: −0.13 to 2.05) for intensity and 0.54 (95% CI: −0.51 to 1.56) for the problem scale. Pre-post effect sizes for each group were more than 1.0, and post-scores on both ECBI scales were in the normative range for children in the technology-enhanced arm. Post-scores on the ECBI Intensity scale, but not the problem scale, were in the normative range for the standard treatment group.
Another RCT evaluated an intervention program (Hitkashrut) combining elements of parent training models including parental self-regulation, involvement of fathers, parent-child communication skills, and behavior management compared with undefined minimal intervention.119 Children were eligible for the study if they scored in the clinical or sub-clinical range on a teacher-rated SDQ. Behavior outcomes on the ECBI for children in the treatment arm (n = 140, mean age: 48.51 (7.35) months] were significantly improved (p<0.001, effect size: 0.76) at 1 month post-intervention compared with the control arm [n = 69, mean age: 48.62 (6.59) months]. At followup of 60 percent of participants (96 in intervention group, 29 in control) 1-year post-intervention, conduct problems were significantly reduced from baseline in the Hitkashrut arm (p<0.001) but not in the control group. The odds of reliable improvement in conduct problems were higher in children in the treatment arm than for those in the control arm (OR=5.09; 95% CI: 2.14 to 12.11) as were the odds of greater improvement in conduct problems from baseline (OR=3.24; 95% CI: 1.30 to 8.02).
One RCT compared the Supportive Expressive Therapy – Parent Child model (n = 27) to the IY-PT program (n = 27).127 Supportive Expressive Therapy entails recognizing and adapting dysfunctional parent responses and expectations for child behavior. Both interventions were conducted among children [mean age: 4.2 (0.96)] referred to an outpatient clinic for externalizing behavior disorders, and groups differed at baseline with significantly greater ECBI and CBCL-rated disruptive behaviors in the IY group compared with control (p=0.013). Outcomes at post-intervention among the 18 treatment group completers and 19 IY completers were improved from baseline in both groups with no significant group differences and mean within-groups effect sizes of 0.66 (0.65) and 1.06 (1.57), respectively (p=NS). Observed child negative behaviors decreased over time in both groups, but group differences were not significant. Seven children in the Supportive Expressive Therapy group and 10 in the IY group no longer met the cut-off for disruptive behaviors in the ECBI or CBCL (exact cut-off used not reported) at post-intervention (p=NS). Improvements in outcomes were maintained at the 1-year followup with no group differences. Eight children in the Supportive Expressive Therapy group and six in the IY group were functioning in the normative range at the 1-year followup (p=NS).
Lastly, one moderate risk of bias RCT compared Tuning into Kids (TIK), described as a 6-week long group program for parents of preschool children, against waitlist clinical treatment as usual control.155 The study sample included 54 children (78% boys) with a mean age of 59.31 (7.38) months. All children had elevated scores on the parent-reported ECBI Intensity score at baseline, with a mean Intensity Score of 169.34 (2.99) in the intervention group and 165.99 (28.82) in the control group. At end of treatment, scores in both groups decreased to 141.26 (23.79) and 157.46 (31.30) for the intervention and TAU groups, respectively (although the group-by-time interaction was not statistically significant). Similar results were reported for the ECBI Problem score [intervention baseline: 23.14 (5.51), end of treatment: 16.86 (6.66); TAU group baseline: 21.00 (8.26), end of treatment: 20.27 (9.04)]. Teacher-rated behavior intensity and problems via the Sutter-Eyberg Student Behavior Inventory were not measured at the end of treatment. At 6-month followup and with two booster sessions after the initial 6-week intervention, mean parent-rated behavior intensity was 148.61 (32.25) and 148.69 (30.36) and behavior problems was 15.57 (9.44) and 16.25 (9.09) for the intervention and control groups, respectively. At 6-month followup, the mean teacher-rated behavior intensity were 101.12 (35.57) and 137.11 (55.39) and behavior problems were 3.94 (6.50) and 10.12 (9.78), for intervention and treatment as usual groups, respectively. The group-by-time interaction was not reported.
Multicomponent Interventions
Of the nine studies evaluating multicomponent interventions for preschool-age children with disruptive behaviors, seven examined PCIT98,99,109,112,114,133,153 and two studies examined another multicomponent intervention.107,154
Parent Child Interaction Therapy (PCIT)
Seven RCTs (reported in 10 publications)98,99,109,112,114,133,153,156,157,161 evaluated a version of PCIT (Table 10). PCIT focuses on improving parent-child interactions to improve disruptive behaviors and combines child-directed play therapy and parent training in behavior management. Studies were conducted in the United States98,99,109,112,114,156,157 and Australia.133,153,161 Five studies (3 high and 2 moderate risk of bias) evaluated a standard version of PCIT.98,109,112,114,153,156 One low risk of bias study evaluated a culturally modified version,99,157 and one study (moderate risk of bias) evaluated an abbreviated version.133,161 Comparison groups included treatment as usual, waitlist control, and alternate versions of PCIT. All of the RCTs measured child disruptive behaviors with the ECBI Intensity subscale and five used a version of the DPICS observation coding system. Five of seven studies also used the ECBI Problem subscale,98,99,109,112,114 and three of the seven studies used the CBCL externalizing scale.98,99,157 Last followup after the end of treatment ranged from 4 months to a mean of 15.90 months.
Five RCTs (3 high and 2 moderate risk of bias) compared standard PCIT intervention with a waitlist control group.98,109,112,153 The first RCT assessed outcomes in children born premature and exhibiting externalizing behavior problems.98,156 Most children were referred to the study by clinical personnel (6% were self-referrals by mothers), and children had to score above the clinically significant range on the CBCL (T-score ≥60) to participate. Fourteen children were randomized to immediate PCIT [mean age: 39.7 (14.2) months] and 14 to the waitlist [mean age: 36.5 (13.0) months]. At the end of treatment assessment (4 months), CBCL and ECBI scores were significantly improved for the PCIT group compared with control (p<0.01). Changes were considered clinically significant (meeting magnitude for reliable change and CBCL T-score <60) in all children in the PCIT group (n = 11 at end of treatment), and in four of 14 children in the waitlist arm. At followup of 10 children in the PCT group 8 months after treatment, eight children maintained clinically significant changes and nine demonstrated continued improvement in behaviors from baseline to the final followup.
Another high risk of bias RCT assessed standard PCIT therapy (n = 37 families) compared with a waitlist control group (n = 27 families) in children with ODD [mean age: 59.2 (12.4) months].109 Sixty-six percent of the children in the study had concomitant ADHD and 22 percent had conduct disorder. Groups differed at baseline on parental IQ, with higher maternal and paternal IQs among parents in the PCIT group compared with control (p<0.05). At the end of intervention (mean 13 sessions over 4 months), scores on the ECBI Intensity and ECBI Problem scales were significantly improved among the 22 families remaining in the PCIT group compared with the 20 remaining in the control group (p<0.05). At 4 months after the end of intervention treatment gains in the PCIT group were maintained, but the study did not assess within- or between-group differences. An earlier paper112 reporting preliminary data on 50 of the 64 families described in the aforementioned paper109 also reported greater improvement in the PCIT group as compared to the waitlist control group on both ECBI scales.
A high risk of bias RCT conducted in Australia randomized families to PCIT or waitlist control.153 The study sample consisted of 34 children with a mean age of 46.52 (6.83) months in the PCIT group and 46.76 (7.50) months in the waitlist control group. Children met diagnostic criteria for ODD and had a disruptive behavior for at least 6 months. Parents were self-referred to participate. Authors reported pre- and post-intervention symptoms measured by ECBI Intensity scale for the PCIT and waitlist control groups and 6-month post-treatment effects for the PCIT group. The mean ECBI Intensity scores from baseline to end of treatment decreased in both the PCIT [baseline: 166.58 (18.93), end of treatment: 125.24 (21.67)] and waitlist control groups [baseline: 173.82 (22.72), end of treatment = 148.35 (19.05)]. Importantly, the mean scores for the PCIT group were in the normal range at end of treatment but the waitlist control group was not (and the difference was statistically significant).
One moderate risk of bias RCT compared children assigned to receive PCIT or to a waitlist control group. The study sample consisted of 30 children with a mean age of 4.53 (0.90) years. Mother ratings from baseline to end of treatment showed greater decrease on the ECBI Intensity scale for the PCIT group [baseline mean: 173(29.5), end of treatment mean: 133(37.7)] as compared to the waitlist control group [baseline mean: 176 (30.2), end of treatment mean: 170 (36.0)] and the ECBI Problem scale [PCIT baseline mean: 23 (5.8), end of treatment mean: 11 (10.7); WLC baseline mean: 25 (5.4), end of treatment mean: 24 (7.5)]. Similar results are reported for the ECBI problem scale. Two RCTs reported on adapted versions of PCIT—one culturally adapted for Mexican-American children (low risk of bias)99,157 and one adapted to include self-directed methods to abbreviate treatment (moderate risk of bias).133,161 The first RCT compared three conditions: standard PCIT [n = 19, mean age: 48.9 (92) months]; PCIT culturally adapted for Mexican-Americans by using cultural references and representations [n = 21; mean age (SD): 54.3(11.6 months]; and treatment as usual, which included cognitive-behavioral therapy (CBT) and family therapy [n = 18, mean age: 55.1 (15.3) months].99,157 Children included in the study were being treated for behavior problems and had a score above the ECBI clinical cut point (more than 127 on Intensity or more than 11 on Problems scale). Overall, 57 percent of families (n = 33) completed the full course of treatment, and 93 percent (n = 54) completed the post-treatment assessments. At the immediate post-treatment assessment, problem behaviors measured on the ECBI and CBCL were significantly reduced in both the PCIT groups compared with treatment-as-usual, but differences between the PCIT arms were not significant. Children improved on the ECBI from baseline in all three groups (ECBI Intensity scale post-treatment effect sizes: 3.38 in adapted PCIT, 2.14 in PCIT, and 1.78 in control; ECBI Problem scale effect size: 2.84 for adapted PCIT, 1.96 for PCIT, and 1.78 for control). Effect sizes at post-treatment on the CBCL were similarly greater than 1 in the PCIT groups and 0.83 in the control group. Outcomes on observational measures of parent and child-led play and compliance were similarly significantly improved in the PCIT groups compared with control, but no different between PCIT arms. Immediately post-treatment, children in the PCIT groups were below the normative mean for behavior problems on the ECBI Intensity scale and CBCL Externalizing scale, and control children were below the clinical cut-offs. At long-term followup of an unstated number of participants at a mean of 15.90 (4.25) and range 6.58 to 24.47 months after the end of treatment, improvements in problem behaviors were largely maintained, with effect sizes on ECBI and CBCL scales ranging from 0.88 to 3.27 across groups and the largest effect sizes in the adapted PCIT group. Differences between groups were not significant in corrected comparisons at long-term followup, although in uncorrected comparisons, behavior outcomes in the adapted PCIT arm were significantly improved compared with the control arm and did not differ from the standard PCIT group.
The second RCT (moderate risk of bias) compared standard PCIT (n = 17 at analysis); an abbreviated version incorporating videotaped trainings (n = 20 at analysis); and a waitlist control group (n = 17 at analysis) in 54 children with a mean age of 46.75 (6.63) months.133,161 Children in the study had to score in the clinical range (≥132) on the ECBI Intensity scale, meet DSM-IV criteria for ODD, and have been referred for treatment for disruptive behaviors of 6 months or longer duration. The standard PCIT intervention was delivered over 15.5 hours while the abbreviated version was delivered in 9.5 hours. Immediately post-treatment, mother-rated ECBI scores were significantly reduced in both PCIT arms (with no significant differences between the PCIT groups) compared with the waitlist control group (p<0.01). Mothers in the standard PCIT arm also rated problem behaviors in the home as significantly reduced post-treatment compared with the waitlist (p<0.05), but such differences were not seen in the abbreviated PCIT arm. Differences were only significant for father-reported ECBI scores between the abbreviated PCIT arm and the waitlist (p<0.05). Group differences on the CBCL were not significant, nor were reports of observations of child problem behaviors. In corrected comparisons, however, no comparisons of parent-rated measures were significant. Treatment gains were maintained at 6-month and 12-month post-treatment followup, with no significant differences between the PCIT groups. At a final, 2-year followup of 10 children in the standard PCIT group and an unstated number in the abbreviated group, group differences continued to be nonsignificant, and mean ECBI scores for all children were in the non-clinical range (mother-rated ECBI effect size: −0.24; father-rated ECBI effects size: −0.21). Fifty-six percent of children in the standard PCIT arm and 68 percent in the abbreviated group continued to meet criteria for ODD, and 67 to 70 percent in each arm met reliable change criteria for reduction in mother-rated oppositional behavior (group differences not significant).
Other Multicomponent Interventions
Two RCTs (both high risk of bias)107,154 evaluated a multicomponent intervention for the treatment of disruptive behavior in preschool-age children (Table 11).
One multicomponent intervention RCT107 evaluated child and maternal outcomes at five time points across 16 months for multiple child and parental interventions. Study participants were 36 children [mean age: 5.67 (1.88) years] with a DSM diagnosis of ODD or conduct disorder whose mothers had sought refuge in a battered women's shelter. Investigators randomly assigned mother-child subject pairs to the intervention group, which received weekly sessions following discharge from a women's shelter and continuing for 8 months. Children and mothers in the intervention group received individualized counseling; mothers also received training in child management skills. Comparison mother-child subject pairs were encouraged through monthly meetings or phone calls to use existing community or shelter services. Groups were similar at baseline for demographic variables and screening measures. Mean CBCL Externalizing scale score at baseline was 66.28 (10.00) in the treatment group compared with 65.56 (9.13) in the comparison group. The treatment group demonstrated a greater rate of decrease in parent reported disruptive behaviors at the third assessment. CBCL score differences between groups were not significant, but the rate of improvement of problems was greater among children in the intervention group compared with the control group. At the fifth assessment (ending the 16-months) the mean CBCL Externalizing scale score was 49.79 (9.17) in the treatment group and 58.59 (13.62) in the comparison group (p=NR). Children in the intervention group (n = NR) moved into the normative range [i.e., less than one standard deviation above the mean CBCL Externalizing T-score for normative group of 50 (10)] on the CBCL Externalizing scale. Control children remained in the clinical range. By the final assessment, 3 of 18 children in the intervention group and 8 of 18 in the control group (p<0.05) had externalizing problems at clinical levels (vs. 13/18 in each group at baseline).
In a second RCT,154 parents were randomized to behavioral family therapy intervention (BFI) or an enhanced group receiving cognitive therapy in addition to the family behavior therapy intervention (CBFI). Both interventions are described as involving both parents and children, although parents are also described as the primary focus of each intervention. Both interventions include teaching a range of positive parenting techniques and strategies for managing misbehavior. The CBFI intervention also includes cognitive therapy components to treat maternal depression. The study sample included 47 families (mean age of children at intake: 4.39 years). All children were diagnosed with either conduct disorder or ODD either alone or in combination with ADHD. There were no significant group-by-time interactions for any parent-reported (CBCL, PDR) or observational measure (Family Observation Schedule), although significant main effects for time were reported for parent reports of child disruptive behavior via CBCL and PDR measures.
School-Age Children
Description of Included Studies
Twenty-nine studies identified as examining psychosocial interventions for school-age children with disruptive behaviors represented in 38 papers. Of the 29 studies, 24 were RCTs96,97,100,101,103,105,108,110,113,117,118,121-123,125,126,128,130-132,134,137,147,165 and five were non-RCTs.88-92 The RCTs were conducted in the United States (n = 9),96,97,100,101,103,105,108,110,113 Norway (n = 4),117,125,126,131 the United Kingdom (n = 3),123,130,147 Canada (n = 2),121,137 Sweden (n = 2),118,122 the Netherlands (n = 2),128,132 Australia (n = 1),165 and Puerto Rico (n = 1).134 Of the non-RCTs, studies, one each was conducted in the United States,90 Australia,91 Ireland,88 Italy,92 and Canada.89 We assessed risk of bias as high for nine studies;88-91,100,117,118,134,165 moderate in 18 studies; 92,96,97,101,103,105,108,110,113,122,125,126,128,130-132,137,147 and low for two studies121,123 (Table 14).
Interventions were categorized as including only a child component (n = 1),132 only a parent component (n = 11),88,90,91,113,117,118,121,122,125,130,147 or as multicomponent interventions (n = 17).89,92,96,97,100,101,103,105,108,110,123,126,128,131,134,137,165
Detailed Analysis
Interventions With Only a Child Component
We included one study (moderate risk of bias) examining interventions with only a child component for school-age children.132 Overall, there was a statistically significant positive result for at least one behavioral outcome132 and one statistically significant positive result for a functional outcome.132 The study included parent-reports of child disruptive behaviors as measured by the CBCL Externalizing subscale and teacher-report (TRF) of child disruptive behaviors.132 Investigators randomly assigned 97 aggressive Dutch boys [mean age: 11.2 (0.93) years] to receive a social cognitive intervention program (SCIP), social skills training (SST), or to a waitlist control group.132 From baseline to post-treatment (11 weeks), there was a significant main effect for time for parent-reported child disruptive behaviors as measured by the CBCL Externalizing subscale [SCIP baseline mean: 66.78 (9.54), SCIP post-treatment mean: 63.31 (10.75); SST baseline mean: 69.73 (6.55), SST post-treatment mean: 61.60 (8.41); WLC baseline mean: 68.29 (5.88), WLC post-treatment mean: 63.71 (7.06)] but not significant effects of the intervention. Significant time by group interactions favoring SCIP were reported for most of these other variables when comparing children treated with SCIP versus SST.
Interventions With Only a Parent Component
Of the 11 studies examining interventions with only a parent component,88,90,91,113,117,118,121,122,125,130,147 eight were RCTs117,121,122,125,147,160,166,167 and three of the studies were non-RCTs.88,90,91 Of the RCTs, two were rated high,117,118 five were moderate113,122,125,130,147 and one study was assessed as low121 risk of bias. The most commonly examined behavioral outcome was general disruptive behavior as measured by parent report using one or more of the CBCL Externalizing scale (n = 4),90,117,125,147,166,167 ECBI Problem subscale,117,122,147,160,167 ECBI Intensity subscale,117,122,147,160,167 SDQ,88,91 or PDR;122,125,160,166 the most commonly used teacher report measure was the TRF externalizing scale.117,125,166 All but one study included at least one of these measures, with the remaining study examining the disruptive behaviors as the percentage of children meeting formal diagnostic criteria for a disruptive behavior disorder using the Schedule for Affective Disorders and Schizophrenia for School-Age Children (KSADS).121 four studies included functional outcomes, with the most commonly examined being child social skills as measured by the Social Skills Rating System,117,125,166 SCS,122 or the Sutter-Eyberg Student Behavior Inventory (SESBI).160
Of the eight studies that measured general disruptive behavior with one or more parent report measure (e.g., CBCL Externalizing, ECBI Intensity, ECBI Problem, or SDQ), each measured a different active treatment. One compared the Parents Plus Children's Programme to treatment as usual and reported that in comparison to treatment as usual the treatment group displayed significant reductions in conduct problems as measured by the SDQ over 8-weeks of active treatment and at 5-month followup.88 One study compared a Skilled Parenting group to a Perceptive Parenting group and reported reductions in conduct problems as measured by the SDQ in both treatment groups but greater reductions in the Skilled Parenting group over 8 weeks of active treatment.91 One study compared a practitioner-directed parent management training program with a self-directed parent management training program and waitlist control group and reported that the practitioner-directed group and the self-directed group were superior to waitlist control group and that the practitioner-directed group was superior to the self-directed group from pre- to post-treatment and at 6-month followup.122 One study compared the Helping the Noncompliant Child intervention to treatment as usual and reported no difference in disruptive behavior improvement between treatment conditions.90 One study compared Parent Management Training – Oregon Model (PMTO) to treatment as usual and reported that PMTO was more effective than treatment as usual from pre- to post-treatment and at one-year followup.125,166 One study compared a brief version of PMTO to treatment-as-usual and reported that brief-PMTO was more effective than treatment-as-usual from pre- to post-treatment.117 One study compared a standard parent-training program to a more intensive version and reported that both treatments showed improvement from pre- to post-treatment but that the intensive version maintained more improvement at 4-year followup.147,167
The one study that measured child disruptive behavior by the proportion of children [mean age: 7.61 (2.62)] meeting formal diagnostic criteria for a disruptive behavior disorder on the KSADS, compared the Strongest Families intervention to treatment as usual and reported that significantly fewer children in the active treatment group met formal diagnostic criteria for ODD than in the treatment as usual group at 240- and 365-days post-randomization.121
Incredible Years – Parent Training (IY-PT)
Three RCTs (1 high and 2 moderate risk of bias) evaluated a version of the IY-PT (Table 15). Two studies examined IY-PT compared to a waitlist control;118,130 one study examined IY-PT + ADVANCE compared to the standard IY-PT program.113 All three studies measured child disruptive behaviors using the ECBI Problem subscale, and two studies also used the ECBI Intensity subscale118,130 and direct observation of child behaviors (but different behavioral observation coding strategies),113,130 and one study used each of the Sutter-Eyberg Child Behavior Inventory-Revised, Intensity subscale,118 the SDQ,118 and CBCL subscales.113
An RCT conducted in Sweden examined 4 to 8 year old children (85% boys) referred for outpatient child and adolescent psychiatry services meeting diagnostic criteria for ODD. Patients were randomized to IY-PT or waitlist control group.118 From baseline to the end of active treatment the children randomized to the IY-PT group showed significantly more improvement on the parent reported ECBI Intensity subscale [baseline mean: 160.0 (20.3); end of active treatment mean: 128.6 (26.5); change: 20% reduction] and Problem subscale [baseline mean: 20.83 (4.17); end of active treatment mean: 11.13 (7.85); change: 47% reduction] than did children in the waitlist control group [ECBI-I baseline mean: 152.9 (23.6); ECBI-I end of active treatment mean: 147.1 (26.0); change: 4%; ECBI-P baseline mean: 20.41 (6.58); ECBI-P end of active treatment mean: 17.53 (8.01); change: 14% reduction]. Significant differences were not reported on the SECBI-R Intensity subscale or the SDQ.
An RCT conducted in the United Kingdom examined 2 to 9 year old children (74% boys) referred to outpatient services for conduct problems and scoring above the clinical cutoff on the ECBI Problem subscale.130 Children receiving IY-PT experienced greater reductions from baseline to post-intervention (14 weeks) on the ECBI Problem subscale [baseline mean: 20.8 (6.5), post-intervention mean: 12.4 (7.8); change: 40% reduction] ECBI Intensity subscale [baseline mean: 152.7 (39.2), post-intervention mean: 130.7 (29.9), change: 14% reduction], and negative behaviors as measured by direct observation [baseline mean: 58.5 (50.6), post-intervention mean: 30.3 (28.6), change: 48% reduction] as compared to children referred to a waitlist control group [ECBI-P baseline mean: 20.3 (7.0), ECBI-P post-intervention mean: 16.3 (8.6), change: 20% reduction; ECBI-I baseline mean: 156.1 (32.9), ECBI-I post-intervention mean: 148.5 (34.7), change: 5% reduction; observed negative behavior baseline mean: 39.9 (37.0), observed negative behavior post-intervention mean: 35.5 (31.5), change: 11% reduction).
One RCT conducted in the United States randomized 3 to 8 year old children (74% boys) scoring above the clinical cutoff on the ECBI, and meeting diagnostic criteria for ODD to receive either IY-PT plus ADVANCE (which includes videotape modeling plus therapist-led discussion focused on family communication, problem solving, and coping skills) or IY-PT.113 Although main effects for time are reported for both mother-reported child disruptive behaviors as measured by the ECBI Problem Score [IY-PT ADVANCE baseline mean: 17.04 (7.02), IY-PT ADVANCE post-treatment mean: 10.08 (7.95), IY-PT ADVANCE short-term followup mean: 9.23 (7.10); IY-PT baseline mean: 15.55 (7.71), IY-PT post-treatment mean: 9.52 (5.94), IY-PT short-term followup mean: 6.79 (4.82)], CBCL Behavior Problems subscale [IY-PT ADVANCE baseline mean: 66.21 (8.97), IY-PT ADVANCE post-treatment mean: 58.58 (10.12), IY-PT ADVANCE short-term followup mean: 57.48 (11.05); IY-PT baseline mean: 64.09 (8.55), IY-PT post-treatment mean: 57.82 (9.60), IY-PT short-term followup mean: 55.94 (8.69)], and CBCL Social Competence subscale [IY-PT ADVANCE baseline mean: 38.48 (10.28), IY-PT ADVANCE post-treatment mean: 45.40 (14.47), IY-PT ADVANCE short-term followup mean: 45.76 (10.73); IY-PT baseline mean: 38.00 (12.58), IY-PT post-treatment mean: 43.06 (13.54), IY-PT short-term followup mean: 40.42 (10.76)] indicating significant improvement from baseline to post-treatment and short-term followup on each measure, there were no significant effects for group or the group-by-time interaction indicating no differences between groups or between groups over time. Trends for father-reported outcomes were similar to those for mother-reported outcomes for each of these measures.
Parent Management Training – Oregon Model (PMTO)
Two RCTs (1 high and 1 moderate risk of bias) examined PMTO.117,125 One study used the CBCL125 and the other study the ECBI117 as its primary measure of child disruptive behaviors (Table 16).
One RCT randomized 4 to 12 year old children (80% boys) in Norway to receive either PMTO or treatment as usual.125 Referrals were made through the normal process at the participating children's services agencies. Children assigned to PMTO experienced statistically significant greater reductions from baseline to post-treatment (11 to 12 months post-baseline) in parent-reported child disruptive behaviors as measured by the CBCL Externalizing scale [PMTO baseline mean: 66.44 (9.09), post-treatment mean: 59.69 (9.44); treatment as usual baseline mean: 65.61 (10.75), post-treatment mean: 61.22 (9.85)], but not as measured by the Parent Daily Report (PDR). No treatment main effect was reported for teacher-reported child disruptive behaviors as measured by the TRF. No treatment main effect was reported for observed child disruptive behavior.
One RCT compared a brief version of PMTO to treatment as usual with 3 to 12 year old children (69.1% boys) whose parents contacted a primary care agency due to disruptive behaviors.117 Results indicated that the brief version of PMTO was more effective than treatment as usual from pre- to post-treatment on parent-reported ECBI, Intensity [PMTO baseline mean: 124.94 (27.57), PMTO post-treatment mean: 106.06 (27.80); treatment-as-usual baseline mean: 124.76 (28.42); treatment-as-usual post-treatment mean: 114.43 (28.79)], ECBI, Problem [PMTO baseline mean: 15.45 (7.16), PMTO post-treatment mean: 9.79 (7.57); treatment-as-usual baseline mean: 15.02 (7.40); treatment-as-usual post-treatment mean: 11.64 (7.88)], and Merrell externalizing subscale [PMTO baseline mean: 74.17 (19.67), PMTO post-treatment mean: 64.56 (17.95); treatment as usual baseline mean: 73.72 (19.84); treatment-as-usual post-treatment mean: 68.58 (19.20)]. No significant group-by-time interactions for child disruptive behaviors as measured by teacher-reported Merrell externalizing subscale were reported.
Other Interventions With Only a Parent Component
In addition to the IY-PT and PMTO studies discussed above, six other studies examined interventions including only a parent component.88,90,91,121,122,147 Three of these six studies measured child disruptive behaviors with the SDQ,88,91,122 two studies used the CBCL Externalizing subscale,90,147 one study used each of the KSADS,121 DBRS-R,121 Ohio Scales subscales,90 and ECBI Intensity and Problem Scales (Table 17).147
One RCT randomized 80 children in Nova Scotia, Canada between the ages of 3 and 7 years (78% boys) with ODD to receive the Parenting the Active Child intervention or treatment as usual.121 The primary outcome was the percentage of children no longer meeting formal criteria for a KSADS-confirmed ODD diagnosis. In comparison to treatment as usual, children with ODD randomized to receive Parenting the Active Child were significantly less likely to meet ODD diagnostic criteria at 120- and 240-days post-treatment, but were not statistically less likely to meet ODD diagnostic criteria at 365-days post-treatment (percentages by group at each time point were not given). DBRS-R scores were not reported.
One RCT compared a practitioner-directed parent management training program (PMT-P) with a self-directed parent management training program (PMT-S) and waitlist control group in a population of 3 to 10 year old children (60% boys) referred to outpatient clinics in Sweden for disruptive behaviors.122 Active treatment was 11 weeks long. Six-month followup data are also provided. In comparison to the children in the waitlist control group, children in both PMT groups experienced statistically significantly greater reductions in parent-reported child disruptive behaviors as measured by the PDR [PMT-P baseline mean: 9.4 (3.8), PMT-P post-treatment mean: 6.0 (4.0), PMT-P 6-month followup mean: 5.0 (3.2); PMT-S baseline mean: 9.7 (3.7), PMT-S post-treatment mean: 7.6 (3.7), PMT-S 6-month followup mean: 6.4 (3.9); WLC baseline mean: 10.6 (3.9), WLC post-treatment mean: 10.1 (4.9), WLC 6-month followup data not reported], ECBI-I [PMT-P baseline mean: 137.5 (20.6), PMT-P post-treatment mean: 118.9 (25.6), PMT-P 6-month followup mean: 115.3 (25.1); PMT-S baseline mean: 137.0 (28.1), PMT-S post-treatment mean: 122.3 (30.8), PMT-S 6-month followup mean: 113.7 (29.7); WLC baseline mean: 140.2 (29.8), WLC post-treatment mean: 139.8 (28.9), WLC 6-month followup data not reported], and ECBI-P [PMT-P baseline mean: 15.5 (5.0), PMT-P post-treatment mean: 10.0 (6.9), PMT-P 6-month followup mean: 8.2 (5.9); PMT-S baseline mean: 15.2 (6.9), PMT-S post-treatment mean: 12.0 (7.5), PMT-S 6-month followup mean: 10.2 (7.1); WLC baseline mean: 16.4 (6.4), WLC post-treatment mean: 16.4 (6.5), WLC 6-month followup data not reported]. No differences were reported in child functional outcomes as measured by the parent-reported Social Competence Scale. Direct comparisons of the PMT-P and PMT-S showed significant between-group effects in favor of PMT-P for child disruptive behaviors as measured by the PDR and ECBI-P (but not the other measures) at post-treatment and that this advantage was stable over the 6-month followup period.
One study using a sequential block design to assign parents of 6 to 11 year old children (80% boys) with disruptive behaviors to the Parents Plus Children's Program (PPCP) or to treatment as usual in outpatient mental health services in Ireland.88 Duration of active treatment was 8 weeks long. In comparison to children receiving treatment as usual, children assigned to the PPCP program experienced greater reductions in parent-reported child disruptive behaviors as measured by the SDQ total difficulties score [PPCP baseline mean: 21.19 (6.15), PPCP post-treatment mean: 18.12 (6.23); TAU baseline mean: 22.34 (7.33), TAU post-treatment mean: 22.15 (8.30)] and conduct problems score [PPCP baseline mean: 5.07 (2.06), PPCP post-treatment mean: 3.92 (1.61); TAU baseline mean: 5.28 (2.12), TAU post-treatment mean: 5.53 (2.46)].
One study assigned parents of children (83% boys) with ODD (mean age: 9.5 years) referred to a mental health clinic in metropolitan Melbourne, Australia to a Skilled Parenting group or to a Perceptive Parenting group according to parent preference.91 Greater reductions in SDQ total difficulties were reported in the Skilled Parenting group [baseline mean: 24.18 (4.70), post-treatment mean: 20.77 (4.77)] than in the Perceptive Parenting group [baseline mean: 24.17 (4.85), post-treatment mean: 23.44 (7.54)] over 8 weeks of active treatment.
One study sequentially assigned parents of 3 to 9 year old children (73% male) referred with disruptive behaviors to an outpatient clinic in Ohio to receive the Helping the Noncompliant Child parent intervention or to treatment as usual.90 Although children in both groups improved on parent-reported measures of child disruptive behaviors, change from baseline to post-treatment in parent-reported child disruptive behaviors as measured by the CBCL Total Problems subscale did not differ significantly between children referred to the Helping the Noncompliant Child intervention group [baseline mean: 68.7 (8.8), post-treatment mean: 64.3 (11.1)] and treatment as usual group [baseline mean: 68.7 (8.4), post-treatment mean: 64.3 (11.3)] or on other parent-reported measures of other constructs.
One RCT randomized 2 to 10 year old children (85% boys) referred for disruptive behaviors to an outpatient clinic in the United Kingdom to receive intensive outpatient treatment or standard treatment.147 The intensive treatment differed from the standard program primarily by its inclusion of 3 5-hour sessions that included individual units and videotaped recording of parent-child interactions in order to give feedback to parents (average service contact 25 hours in 11 visits over 24 weeks) to the standard outpatient treatment (average service contact 7 hours in 6 visits over 24 weeks). Child disruptive behavior was measured by parent-reported CBCL Externalizing subscale. Parent-reported child disruptive behaviors as measured by the CBCL mean Externalizing T-score for the standard treatment group [baseline mean: 75.3 (5.9), post-treatment: 67.0 (9.23)] and intensive group [baseline mean: 74.2 (9.28), post-treatment mean: 63.9 (11.1)] both decreased from baseline to post-treatment and statistical models showed a main effect for time but no group-by-time interaction. Importantly, only the intensive treatment group had a mean score below the clinical cut-off at post-treatment. A companion paper reporting 4-year followup reported that the intensive treatment group's mean CBCL Externalizing scores remained below the clinical cutoff and that the standard treatment group meaning CBCL scores had worsened such that improvement from baseline was no longer evident at 4-year followup.167
Multicomponent Interventions
Of the multicomponent intervention studies (n = 17), four studies105,110,126,131 examined IY components delivered in combination with each other (IY-PT + IY-CT in three and IY-PT + IY-CT + IY-TT in one); two studies128,134 assessed the Coping Power Program; two studies97,101 examined the effects of a modular treatment for children with ODD or CD; two studies89,137 evaluated the SNAP Under 12 Outreach Project; and seven studies92,96,100,103,108,123,165 evaluated a different multicomponent intervention.
Incredible Years (IY)
Four studies examined IY components delivered in combination with each other (3 studies of IY-PT + IY-CT; 1 study of IY-PT + IY-CT + IY-TT) for school-age children (Table 18).105,110,126,131
One RCT randomized 4 to 8 year old children (80% boys) referred to two child psychiatry outpatient clinics in Norway due to oppositional or conduct problems to IY-PT, IY-PT plus IY-CT, or to a waitlist control group.126 Mother-reported child disruptive behaviors as measured by the ECBI Intensity scale were significantly reduced for IY-PT [baseline mean: 157.1 (24.2), post-treatment mean: 116.5 (27.0)] as compared to the waitlist control group [baseline mean: 159.7 (23.1), post-treatment mean: 137.3 (28.6)] but no significant difference between the IY-PT plus IY-CT [baseline mean: 156.5 (22.0), post-treatment mean: 121.8 (31.9)] and waitlist control group. Mother-reported aggressive behavior as measured by the CBCL Aggression subscale was significantly reduced for the IY-PT [baseline mean: 18.8 (6.8), post-treatment mean: 110 (7.0)] and IY-PT + IY-CT [baseline mean: 21.7 (7.0), post-treatment mean: 13.7 (8.6)] as compared to the waitlist control group [baseline mean: 20.0 (7.7), post-treatment mean: 17.2 (8.2)]. No significant between-group difference was reported for mother-reported ECBI-P. Generally, father-reported child disruptive behaviors correlated strongly with mother-reports.
One RCT included 4 to 8 year old children (80% boys) referred for treatment to two child psychiatric outpatient clinics in Norway by parents due to disruptive behaviors.131 Children and their parents were randomized to receive IY-PT, IY-PT + IY-CT, or to a waitlist control condition. The PT groups lasted 12-14 weeks. The CT sessions took place over 18 weeks. Results indicate a significant main effect for group on teacher-reported aggression as measured by the Preschool Behavior Questionnaire (PBQ) for children in day care and the aggression subscale of the TRF for children in school from baseline to post-treatment, co-varying baseline scores [PT + CT baseline mean: 3.0 (1.6), PT + CT post-treatment mean: 1.8 (1.5); PT-only baseline mean: 2.7 (1.7), PT-only post-treatment mean: 2.5 (1.4); WLC baseline mean: 3.2 (1.6), WLC post-treatment mean: 3.1 (1.6)]. Teacher-reported child disruptive behavior was significantly reduced in the PT + CT group in comparison to the PT-only (p<0.05) and waitlist control (p<0.01) groups but the PT-only and waitlist control groups did not significantly differ.
One RCT randomly assigned 4 to 8 year old children (75% boys) referred to an outpatient university research clinic in the United States with conduct problems to receive IY-CT, IY-PT, combined IY-CT + IY-PT, or to a waitlist control condition.110 Families were assessed at baseline and 8 months post-baseline (2 months after 6 months of active treatment), and 1-year post-treatment (e.g., 1.5 years post-baseline). At 1-year post-treatment followup, there were significant effects for time for all three active treatment groups on all mother and father-reports of child disruptive behaviors (CBCL Total Behavior problems score, ECBI Intensity score, and PDR score), and child social problem solving via WALLY but no significant group-by-time interactions for any of these variables. Considering all effects together, the IY-CT + IY-PT was superior to IY-CT in that it had an effect on parenting and child behaviors, and was superior to IY-PT in that it had an impact on child social problem solving.
One RCT examined the effect of IY-PT + IY-CT +IY-TT when delivered together in comparison to other combinations of IY components, to individual IY components, and to a waitlist control condition in 4 to 8 year old children (90% boys) with ODD who were referred by their families to an outpatient university research clinic in the United States.105 Children were randomly assigned to one of the following treatment conditions: IY-PT; IY-PT + IY-TT; IY-CT; IY-CT + IY-TT; IY-PT + IY-CT + IY-TT; or a waitlist control. Although the study mainly reports results from composite measures made up of a number of previously validated measures (composite measures) because they are not themselves validated measures, are excluded from this report, it also reports the percentage of children showing clinically significant improvements at 6 months (post-treatment) and 1-year followup. At 1-year followup (e.g., the last followup), the treatment arms with the highest proportion of children showing clinically significant improvements on mother-reported ECBI-I scores were the IY-PT +IY-TT (84.6%) and IY-CT + IY-TT (81.3%) groups, but the only significant contrasts were between the IY-PT + IY-TT and IY-PT groups (with the combined treatment showing greater change) and the IY-CT group showing more improvement than the IY-PT group. It should also be noted that on teacher reported aggression via the TASB that the IY-CT group was more likely to have shown clinical improvement than the IY-PT + IY-CT + IY-TT group.
Coping Power Program
Two studies128,134 assessed the Coping Power Program (Table 19).
One RCT assigned children ages 8 to13 years referred for disruptive behaviors to one of four child psychiatric outpatient clinics or three mental health centers in the Netherlands over a 3-year period to receive either the Coping Power Program (CPP) or treatment as usual.128,168 Significant group-by-time interactions were reported only for PDR overt aggression subscale [CPP baseline mean: 2.90 (1.51), CPP post-treatment mean: 1.90 (1.38); treatment as usual baseline mean: 2.46 (1.53); treatment as usual post-treatment mean: 2.05 (1.43)], but not for the other parent-reported measures of child disruptive behavior (e.g., PDR oppositional behavior subscale, CBCL Externalizing Behavior subscale) or for the teacher-reported measure of child disruptive behavior via the TRF externalizing behavior subscale. At 5-year followup, there were no significant differences between the CPP or TAU groups on the NYS Delinquency Scale [CPP mean: 1.2 (1.5); TAU mean: 1.5 (1.5)], but children in the CPP group did report being less likely than children in the TAU group to smoke cigarettes in the past month (CPP % smoked in the last month = 17; TAU % smoked in the last month = 42) and lifetime use of marijuana (CPP % with lifetime marijuana use = 13; TAU % with lifetime marijuana use = 35).168
A second RCT randomly assigned 278 children from 8 to 13 years of age in Puerto Rico who met DSM-IV-TR criteria for a disruptive behavior disorder to receive a culturally sensitive cognitive behavioral intervention (n = 174) or to a waitlist control group (n = 104).134 Behavioral outcomes were measured with the Irritability / Hostility subscale of the Bauermeister School Behavior Inventory. Although boys and girls in the treatment group demonstrated more improvement on this subscale score over 12 weeks of than did children in the control group, these differences were not statistically significantly different.
Modular
Two studies97,101 (each including multiple papers) examined the effects of a modular treatment for children with ODD or CD (Table 20). The modular treatment included seven components: (1) child CBT/skills training, (2) child medication for ADHD, (3) parent management training, (4) parent-child / family therapy, (5) school programming/teacher consultation, (6) peer relations/community activities development, and (7) case/crisis management.
One RCT included children aged 6 to11 years (85% boys) referred for disruptive behavior disorders to program sites associated with a university medical center in the United States.101 Children and families were randomly assigned to receive the modular treatment either in the community or in an outpatient research clinic setting. Healthy controls were included to provide norms for self-report questionnaires. Results suggest significant improvement in both groups from baseline to post-treatment (6 months) on measures of child disruptive behaviors including the CBCL Externalizing subscale, IOWA Conners Rating Scale oppositional defiant subscale, Self-Report of Antisocial Behavior (SRAB), TRF externalizing behavior, and Child and Adolescent Functional Assessment Scale (CAFAS). There were not group-by-time interactions from baseline to post-treatment or at 3-year followup for any measures indicating that the modular treatment can be successfully implemented in a research clinic or community based setting.
One RCT examines the effectiveness of the same modular treatment adapted for implementation by nurses in primary care settings.97 To examine this, children aged 6 to 11 years (65% boys) were enrolled based on parent concerns about disruptive behaviors and scores on the Pediatric Symptoms Checklist (or PSC-17) above the clinical cutoff for externalizing behavior problems to either the nurse-administered modular care (PONI) or to enhanced usual care (EUC). From baseline to 1-year followup, significant group-by-time interactions were seen on the Individualized Goal Achievement Rating (IGAR) average [PONI baseline mean: 1.0 (0.0), post-treatment mean: 2.8 (0.8); EUC baseline mean: 1.0 (0.0), EUC post-treatment mean: 2.6 (0.8)] and Child Health and Illness Profile (CHIP) total score [PONI baseline mean: 47.3 (5.9), PONI post-treatment mean: 49.5 (5.9); EUC baseline mean: 48.7 (6.0), EUC post-treatment mean: 48.9 (6.1)], but not on the parent-reported PSC-17 externalizing score, parent-reported SDQ total score, or teacher-reported SDQ total score even though both groups reported change over time for almost all of these measures.
SNAP Under 12 Outreach Project (SNAP Under 12 ORP)
Two studies evaluated the SNAP Under 12 in Canada (Table 21).89,137
One RCT included children (mean age approximately 9 years; approximately 75% boys) who had police contact within 6 months of referral and/or a T-score on the CBCL Delinquency subscale indicating behavior problems more serious than 98 percent of same-age and same-sex peers.137 Children were randomized to receive the SNAP Under 12 12-week outpatient program or to a waitlist control group that participated in a recreation group called the Cool Runner's Club. From baseline to 3 months, children in the SNAP Under 12 group experienced significantly greater declines in parent-reported child disruptive behaviors as measured by the CBCL Delinquency [baseline mean: 8.9, 3-month mean: 4.9, SDs not given] and aggression [baseline mean: 18.8, 3-month mean: 15.5, SDs not given] subscale mean scores than did children referred to the waitlist control group [delinquency subscale baseline mean: 8.9, delinquency subscale 3-month mean: 8.4; aggression subscale baseline mean: 19.4, aggression subscale 3-month mean: 19.0, SDs not given]. At the 3-month point, the two groups switched treatments and from 3 months to 18 months, the children originally referred to SNAP Under 12 continued to make progress and the children originally referred to the waitlist control (who were now receiving SNAP Under 12) also showed improvement (although they never caught up to the other group) on the same measures.137
In a second study, investigators recruited boys ages 6 to 11 years from the community to participate in SNAP Under 12 using similar inclusion and exclusion criteria as described in the previous study but allocated children to SNAP Under 12 or the waitlist control recreation group on a first-come, first-served basis rather than being randomized.89 In comparison to children initially referred to the waitlist control condition, children initially referred to the SNAP Under 12 showed significantly more improvement on parent-reported child disruptive behaviors as measured by the CBCL Rulebreaking, Aggressive, Conduct Problems, and Total Problems subscales, but not on the CBCL Competence subscale or TRF outcomes.
Other Multicomponent Interventions
Seven studies, each evaluating a different multicomponent intervention, were also identified (Table 22).92,96,100,103,108,123,165
One RCT evaluated the effectiveness of a CBT as compared to an educational fire safety intervention or a home visit from a firefighter for fire-setting behavior in 54 boys aged 5 to 13 years and referred due to documented fire-setting behavior by the City of Pittsburgh Bureau of Fire, direct parental solicitation, or a mental health practitioner.108 Children in each of the three intervention groups showed significant improvement on measures of fire involvement, interest and risk, but CBT and fire safety intervention were not more effective at reducing fire-setting behaviors even though the group-by-time interaction approached statistical significance (p<0.06).108
One RCT assigned children between the ages of 4 and12 years (68% boys) clinically referred to an outpatient mental health clinic specializing in the treatment of disruptive behavior disorders at a university teaching hospital and meeting criteria for ODD to receive Collaborative Problem Solving (CPS) or parent training based on Barkley's (1997) 10-week behavior management program.103 The primary measure of child disruptive behavior was the parent-rated Oppositional Defiant Disorder Rating Scale (ODDRS). On this measure of parent-reported child disruptive behaviors, there was a significant change from baseline to post-treatment and from baseline to 4-month followup for children in the CPS group, but the group-by-time interactions from baseline to post-treatment and from baseline to 4-month followup were not significant (means for both groups at each time point are not given). The group-by-time interactions on the Parent-Child Relationship Inventory (PCRI), a measure of one of this reviews functional outcomes, was also not significant.
One RCT assigned children between 8 and11 years (73% boys) with mood disorders and their families to receive either treatment as usual plus immediate treatment in the multifamily psycho-education program (MF-PEP) or treatment as usual plus waitlist control.96 Disruptive behaviors were measured with the Children's Interview of Psychiatric Syndromes (ChIPS) and Parent Form (P-ChIPS). Although MF-PEP was associated with a significant decrease in ODD symptoms from baseline to 12 months followup, there was no significant difference between the MF-PEP [baseline mean: 5.7 (2.1), 12-month followup: 4.5 (2.6)] and the waitlist control groups [baseline mean: 5.4 (2.6), 12-month followup: 4.9 (2.7)] on ODD symptoms. There was also no difference in CD symptoms from baseline to 12-month followup.
One RCT assigned parents of children with a mean just over 5 years of age (71% boys) who were screened for disruptive behaviors with the SDQ in schools in London to either receive the Supporting Parents on Kids Education in Schools (SPOKES) intervention or to receive access to a telephone hotline designed to help parents access treatment as usual in the community over 28 weeks of active treatment.123 In comparison to children in the control group, children receiving SPOKES had significant reductions in child antisocial behavior as measured by parent interview [SPOKES baseline mean: 1.15 (0.44), SPOKES post-treatment mean: 0.91 (0.36); treatment as usual baseline mean: 1.12 (0.49), treatment as usual post-treatment mean: 1.13 (0.49)], parent-reported child disruptive behavior as measured by the ECBI Intensity subscale) [SPOKES baseline mean: 119.1 (31.6), SPOKES post-treatment mean: 103.9 (27.3); treatment as usual baseline mean: 115.9 (27.0), treatment as usual post-treatment mean: 113.2 (31.3)], but little difference in teacher-reported oppositional symptoms as measured by a DSM-IV questionnaire items.
An additional RCT examining Project Support and was conducted in the United States. Authors examined the effectiveness of Project Support, a family intervention specifically designed to reduce disruptive behaviors in the children of women at a domestic violence shelter.100 The intervention provides mothers with child behavior management skills and instrumental and emotional support.100 Although therapists worked primarily alone with mothers, children were regularly included in sessions so that mothers' skill using the new techniques could be evaluated and additional skill building activities could be tailored according to the child's response to them. Child conduct problems were measured by two maternal self-report measures (CBCL Externalizing and ECBI Intensity). Mean CBCL Externalizing scale scores decreased from 67.9 to 57.4 pre- to post-treatment for the Project Support group and from 65.9 to 61.6 for the treatment as usual control group (Cohen's d=0.66) and from 142.1 to 102.5 and 129.8 to 102.7 on the ECBI Intensity scale (Cohen's d=0.17), respectively.
One moderate risk of bias, prospective cohort study92 compared children sequentially assigned to a multimodal treatment program (MTP), which includes once a week sessions for 1 year of individual and group support for children and individual parent training, or treatment as usual (TAU). The study sample consisted of 135 youth with a mean age of 12.0 (2.5) years. Mean CBCL Externalizing scores decreased in the MTP group from 69.73 (7.43) at baseline to 65.58 (7.34) at end of treatment and from 71.49 (7.25) at baseline to 68.58 (7.62) at end of treatment in the treatment as usual group. Mean CBCL Aggressive Behavior scores decreased in the MTP group from 71.67 (9.03) at baseline to 66.81 (8.52) at end of treatment and from 74.06 (9.77) at baseline to 71.17 (10.00) at end of treatment in the TAU group. The mean CBCL Delinquent Behavior scores decreased in the MTP group from 66.03 (8.07) at baseline to 63.42 (7.51) at end of treatment and in the TAU group from 67.90 (8.31) at baseline to 65.20 (7.92) at end of treatment. This group-by-time interaction was not statistically significant.
Finally, one high risk of bias RCT165 compared children assigned to a reciprocal skills training (RST), a family-based treatment, against children assigned to a waitlist control group. The study sample consisted of 57 children with a mean age of 8.47 (1.6) years. The intervention group consisted of children referred from a clinic setting and from a pre-treatment hospital setting. Because studies of inpatient hospital settings are excluded from this review, only results for the clinic setting are reported here. On the parent-reported CBCL Externalizing scale, mean scores for the clinic-referred RST group decreased from 67.4 (7.0) at baseline to 59.8 (11.5) end of treatment and from 70.0 (5.8) to 74.0 (5.0) for the waitlist control group. The group-by-time interaction effect was statistically significant. In addition, the percentage of children who no longer met DSM-IV criteria for oppositional defiant disorder was significantly reduced in the clinic-referred RST group than in the waitlist control group (72.2% vs. 30%, p<0.01).
Teenage Children
Description of Included Studies
We identified 14 studies,86,94,104,106,111,115,116,120,124,136,142-144,146 reported in 17 papers86,94,104,106,111,115,116,120,124,136,142-144,146,169-171 that evaluated psychosocial interventions for teenagers with disruptive behaviors. Of the 14 included studies, 13 were RCTs (4 high, 5 moderate, and 4 low risk of bias)94,104,106,111,115,116,120,124,136,142-144,146and one was a retrospective cohort study (high risk of bias).86 Six of the studies were conducted in the United States;94,104,106,111,115,116 three were conducted in Germany;142-144 two were conducted in the Netherlands;86,136 and one each in the United Kingdom,120 Israel,146 and Sweden.124 One study included only a child component.104 The other 13 studies were multicomponent interventions (Table 25). Of these multicomponent interventions, six were family interventions106,115,116,142-144 and five were Multisystemic Therapy (MST).94,111,120,124,136 We categorized the other two multicomponent intervention studies as an “other” multicomponent intervention.
Detailed Analysis
Interventions With Only a Child Component
One single center, RCT (high risk of bias) conducted in the United States examined an intervention with a child component only.104 This study examined the efficacy of the Adolescents Coping with Depression (CWD-A) course in a population of non-incarcerated adolescents between 13 and 17 years meeting DSM-IV criteria for comorbid conduct disorder and depression (n = 93). These results were compared to a control condition utilizing a group intervention focused on life skills and tutoring (LS) only. The CWD-A is a group-based cognitive behavioral intervention typically directed towards depressive symptoms. However, his study also examined its impact on disruptive behavior. Participants were randomized to receive either the CWD-A course (n = 45) or the control LS intervention (n = 48). Approximately 10 adolescents per group (CWD-A group mean: 10.4 participants; LS mean: 9.4 participants) were treated in sixteen 2-hour sessions over the course of 8 weeks. They were then assessed post-treatment and at 6- and 12-month followup using the following dimensional outcome measures: the Beck Depression Inventory-II (BDI-II), the Hamilton Depression Rating Scale (HDRS), the Externalizing Problem Subscale of the Child Behavior Checklist (CBCL), the Children's Global Assessment Scale (CGAS), and the Social Adjustment Scale-Self Report (SAS-R). Mean (SD) age of participants was 15.1 (1.5) years for those in the CWD-A group and 15.1 (1.3) years in the LS control group and 55 percent in the sample were male. Comparing baseline demographic and clinical characteristics, the two randomized groups only differed significantly in gender, the CWD-A group consisting of 60 percent females compared to only 38 percent females in the LS condition. Thus, gender was included as a covariate during analysis.
From baseline to the end of active treatment at 12 months, the children randomized to the CWD-A intervention group showed significant improvement compared to the LS control group in the depressive outcome measures (BDI-II, HDRS, SAS-R). However, no significant reductions were reported in disruptive behaviors as measured by the parent-reported CBCL Externalizing subscale, or in social functioning, as measured by the CGAS.
Multicomponent Interventions
Of the 13 studies of multicomponent interventions for teenage children, six studies examined family interventions including the Brief Strategic Family Therapy (n = 3),106,142,144 Parenting with Limits and Love,116 a family behavior therapy intervention,115 and a general family therapy approach (n = 1).143 Five of the multicomponent intervention studies evaluated Multisystemic Therapy (MST).94,111,120,124,136 The two other studies each examined a different multicomponent intervention.86,146
Family Therapy
Six studies examined the impact of family therapy interventions on disruptive behaviors and other related outcomes (Table 26).106,142-144 Three of these studies were conducted in Germany142-144 and three were conducted in the United States.106,115,116 Two of the studies measured disruptive behaviors using the self-reported Adolescent Risk Taking Behavior Scale (ARBS),142,143 while another study used the conduct disorder and socialized aggression subscales of the parent-reported Revised Behavior Problem Checklist (RBPC) behavior problem scale.106 Three studies also measured levels of anger and anger expression using the self-report State-Trait Anger Expression Inventory (STAXI)142-144 Three studies also included outcomes related to health related quality of life,142-144 two included interpersonal functioning outcomes142,143 and one measured the impact of the intervention on family functioning.106
Three of the four studies examined the delivery of BSFT and its impact on disruptive behavior problems and related outcomes.106,142,144 In each of these studies the intervention group receiving BSFT was compared to a control group intervention in which the participants received either group therapy106 or another family-based intervention.142,144 Each of these studies examined the use of BSFT with a specific population. One study106 compared the effectiveness of BSFT for a primarily male Hispanic adolescent population (n = 126, mean age: 15.6 years; 75% male) with a general group therapy based intervention. Participants were included based on parental or school complaints of externalizing behavior problems. Compared to the control group, participants receiving the BSFT intervention displayed a significantly greater reduction in behavior problems as measured by the Revised Behavior Problem Checklist (RBPC). Compared to 11 percent of clinically significant improvement in the control group (p=NS), 43 percent of the BSFT group showed reliable improvement in Conduct Disorder measures (p<0.001). Similarly, on the Socialized Aggression scale, 36 percent of BSFT recipients showed reliable improvement (p<0.001) compared to 11 percent of the control population (ns). The treatment group also reported significant reductions in substance use and increased improvements in family functioning as compared to the control group.
Two studies evaluated the impact of BSFT on bullying behaviors: one142 in a population of adolescent females and the other144 with adolescent males. The first study compared the effectiveness of BSFT on bullying behavior in a group of 15 year old girls [n = 40, mean age: 15.5 (0.5) years] who had shown direct verbal and/or physical bullying behavior for at least six months to a placebo intervention. The study assessed risk-taking behaviors using the Adolescent Risk Taking Behavior Scale (ARBS), which consisted of seven behavior scales: drug use, smoking, binge drinking, excessive media use, having sex without a condom, having sex while using drugs and alcohol and sexual disinhibition. The study found that girls receiving the BSFT showed significantly greater reductions in adolescent risk taking behavior than those receiving the placebo treatment at both the end of treatment (ARBS score mean difference between groups: −9.3, p<0.001) and after a one year followup assessment (ARBS score mean difference between groups: −8.2, p<0.001). BSFT also led to significant improvements in interpersonal relationships as measured by the Inventory of Interpersonal Problems (IIP-D), as well as reducing levels of anger (STAXI) and increasing health related quality of life (SF-36) as compared to the placebo intervention. These results were reported to have remained relatively stable at one-year followup.
One study143 examined the effectiveness of family therapy as a monotherapy for reducing disruptive behaviors and anger compared to a placebo intervention. This study utilized an integrative family therapy model that integrated elements from family systems theory, psychodynamic-oriented therapy, gestalt therapy, and behavioral therapy. Interventions were focused around communication, family rules and each family member's role in the existing problematic family system presentation. Forty-four male adolescents [mean age: 15.2 (0.5)] displaying bullying behavior participated in the study, half randomly assigned (n = 22) to receive a family therapy program for 6 months and the other half assigned (n = 22) to the placebo control group for the same length of time Consistent with the results from the female [mean age: 15.5 (0.5)] cohort study,142 this study reported significantly greater reductions in adolescent risky behaviors on all scales of the ARBS (end-of-treatment ARBS score mean difference: −6.3, p<0.001; followup ARBS score mean difference: −3.1, p<0.001) and significant reductions in anger levels on nearly all of the scales measured by the STAXI. Additional reported outcomes included significant improvements in interpersonal relationships, as measured by six of the eight scales on the IIP-D, and significant improvement in health related quality of life (SF-36) as compared to the placebo control group.
One high risk of bias RCT115 compared children assigned to family-behavioral therapy with children assigned to individual cognitive therapy. The study sample consisted of 56 children with a mean age 15.4 (1.3) years. On the parent-reported CBCL Delinquency scale children assigned to the family-behavioural therapy group experienced greater reductions [baseline mean score: 74.44 (6.70); end of treatment mean score: 63.55 (9.10)] than did children assigned to the individual cognitive therapy group [baseline mean score: 77.40 (8.45); end of treatment mean score: 66.67 (12.11)]. These differences were maintained at 6-month followup. Similar findings were also evident via the parent reported ECBI Problem scale (family behavioural therapy group baseline mean score: 17.86 (8.52); family behavioural therapy group end of treatment mean score: 8.58 (9.09); individual cognitive therapy group baseline mean score: 21.52 (6.12), individual cognitive therapy group end of treatment mean score: 11.95 (9.46)], and ECBI Intensity scale (family behavioural therapy group baseline mean score: 133.55 (38.26); family behavioural therapy group end of treatment mean score: 90.78 (36.37); individual cognitive therapy group baseline mean score: 145.93 (35.58); individual cognitive therapy group end of treatment mean score: 110.35(45.92)].
One moderate risk of bias RCT116 compared Parenting with Limits and Love (PLL), a 6-week group therapy program integrating principles of a structural family therapy approach, against a control group receiving TAU probation services including counseling, community schools, and/or community service. The study sample included 38 teenagers [mean age: 15] (57% boys) who had been referred for criminal offenses. Disruptive behaviors were assessed via the parent-reported CBCL. Mean scores in the intervention group showed greater decrease than in the control group on the CBCL Externalizing subscale (intervention group baseline mean score: 64.07 (15.80), intervention group end of treatment mean score: 56.57 (11.21); control group baseline mean score: 73.08 (9.54), control group end of treatment mean score: 71.83 (10.11)], aggressive behaviors scale (intervention group baseline mean score: 67.43 (12.77), intervention group end of treatment mean score: 58.14 (6.78); control group baseline mean score: 70.83 (14.22), control group end of treatment mean score: 71.67 (13.01)], and rule-breaking behaviors scale (intervention group baseline mean score: 67.29 (10.94), intervention group end of treatment mean score: 60.07 (8.07); control group baseline mean score: 75.33 (7.30), control group end of treatment mean score: 69.33 (9.44)]. The group-by-time interaction for each of these measures was statistically significant.
Multisystemic Therapy
Of the five studies that examined MST, two were conducted in the United States,94,111 and one each in the Netherlands,136 the United Kingdom,120 and Sweden.124 All five of these studies were RCTs (1 high, 2 moderate, and 2 low risk of bias). Overall, the treatment effects were positive, with only one study124 not demonstrating significance (Table 27).
One study94,172 conducted in the United States randomly assigned 164 adolescents (83% male) between the ages of 11 and 18 years in one school system's self-contained behavior intervention classrooms to receive MST or treatment as usual. Treatment as usual included behavior management interventions and support provided as part of the classroom structure. At 18-month followup, parent-reported CBCL Externalizing mean scores for the MST group [baseline mean: 25.90 (10.63); end of active treatment mean: 18.20 (10.82); change: 30% reduction] decreased significantly more from baseline to end-of-treatment than those of the control group [baseline mean: 23.40 (9.61); end of active treatment mean: 19.19 (10.36); change: 18% reduction]. The outcomes from the YSR assessment showed similar results, with the MST group [baseline mean: 17.63 (9.03); end of active treatment mean: 13.87 (8.53); change: 21% reduction] showing greater effects than the control group [baseline mean: 17.00 (7.97); end of active treatment mean: 14.22 (7.72); change: 16% reduction]. No significant effect was found based on the TRF of externalizing behaviors or arrest data.
One pretest-posttest control group design (moderate risk of bias)111 conducted in the United States compared the effects of MST to individual therapy (IT) on criminal behavior and violent offenses among a group of high-risk juvenile offenders (n = 176, 67% male). Ninety-two participants [mean age: 14.8 (1.5)] were randomly assigned to receive MST, with 77 completing both pre- and post-treatment assessments and receiving an average of 23.9 (8.2) hours of treatment. Out of the 84 participants initially assigned to the IT control group, 63 completed both assessments and received an average of 28.6 (9.8) hours of treatment.
This study demonstrated MST to be significantly more effective than individual therapy based on several outcome measures. From pre-treatment to post-treatment, both mothers and fathers from the MST group showed significant decreases in psychiatric symptomology as measured by the SCL-90-R [mother mean baseline score: 0.12 (1.02); mother mean post-treatment score: −0.15 (0.97); father mean baseline score: −0.06 (0.90); father mean post-treatment score: −0.07 (0.77)]. Their IT counterparts did not show similar reductions in psychiatric symptomatology for either of the parents [mother mean baseline score: 0.04 (1.17); mother mean post-treatment score: 0.20 (1.26); father mean baseline score: 0.06 (1.05); father mean post-treatment score: 0.19 (1.09)]. The study also showed a significant interaction effect for mothers' reports of adolescent disruptive behaviors as measured by the Revised Behavior Problem Checklist (RBPC), with mothers in the MST group reporting a decrease in adolescent behavior problems and mothers of youths in the IT group reporting an increase in behavior problems. Additionally, adolescents in the MST group showed significant positive change in family functioning and cohesion (FACES-II), lower re-arrest rates, and less serious offenses when rearrested. The pattern of lower frequency and decreased seriousness of crimes emerged in both the analysis of the entire sample as well as when analyzing only those that completed treatment.
Three studies120,124,136 examined the effectiveness of MST to treatment as usual in more socialized systems offering comprehensive management of disruptive behavior problems (i.e., United Kingdom, Sweden, and The Netherlands). One low risk of bias study120 conducted in the United Kingdom compared MST to outcomes for youth working with a Youth Offending Team (YOT). YOTs, like MST, provide a multicomponent intervention that is led by a social worker working with additional team members, such as therapists and probation officers. This study examined the impact of MST versus YOT, or usual services, on offending behavior based on police records (primary outcomes), as well as parent and youth rated reports of disruptive and delinquent behaviors as measured by the CBCL and YSR (secondary outcomes). A group of 108 adolescents between 13 and 17 years of age were allocated to receive either MST [n = 56; mean age: 182.7 (12.3) months; 91% male] or YOT [n = 52; mean age: 180.6 (12.9) months; 90% male]. Based on data derived from police computer records, youth who participated in MST had significantly less nonviolent offending by the end of the followup period (18 months post treatment end). There were no significant differences with regard to violent offending given the low number of youth with violent offense records.
In regards to secondary outcome measures, assessments from baseline to 6 months post-treatment indicated that, for internalizing and externalizing problems, there was no significant difference in disruptive behaviors between the two groups. However, the CBCL scales pertinent to the hypothesis each showed significant interactions favoring MST. For the aggression subscale, MST participants showed significantly more improvement [baseline mean: 69.4 (12.9); 6-month mean: 64.2 (11.4); change: 7.5% reduction] than the YOT group [baseline mean: 66.9 (11.6); 6-month mean: 65.9 (11.9); change: 1.5% reduction]. Similar results occurred with the delinquency subscale, with MST participants again showing significant reductions in [baseline mean: 73.4 (8.3); 6-month mean: 67.9 (8.6); change: 7.5% reduction] compared to the YOT group [baseline mean: 73.0 (7.9); 6-month mean: 70.9 (8.5); change: 2.9% reduction]. Analysis of rates of change also indicated moderate effect sizes in the MST group (aggression effect size: 0.42; delinquency effect size: 0.64) and smaller effect sizes for the YOT group (aggression effect size: 0.09; delinquency effect size: 0.25). While the parent-reported outcomes suggested improvement in disruptive behaviors in the MST group, none of the scales from the YSR yielded significant interactions. Data regarding longer-term follow up of rate of disruptive behavior were not available.
One multicenter low risk of bias study124 examined the effectiveness of MST to treatment as usual in Sweden. Treatment as usual for court-referred youth in Sweden includes referral for social service supports, which work to identify treatment needs. Treatment in the control group was varied and was primarily represented by individual therapy, family therapy, mentoring, or no services. A group of youths between the ages of 12 and 17 fulfilling diagnostic criteria for conduct disorder [n = 156; mean age: 15.0 (1.4) years; 61% male] were randomized to either the treatment (n = 79) or control group (n = 77). Mean enrollment in MST lasted 145.8 (51.6) days. Disruptive and delinquent behavior was assessed by both caregiver and adolescent ratings through the CBCL and YSR, respectively. Additionally, the study looked at delinquency through the Self-Report Delinquency Scale (SRD), substance use measures through multiple self-reporting methods (i.e. AUDIT/DUDIT), and relationships and social competence (i.e. Pittsburgh Youth Study, SCPQ, Social Skills Rating System, school attendance). Pre- to posttest measurements did not demonstrate any significant differences in the MST intervention compared to treatment as usual as measured by the CBCL and YSR measures, nor on the SOC scale. Both groups showed decreased disruptive and delinquent behavior, improvement in social skills and better family relations.
One RCT (high risk of bias)136 examined the effectiveness of MST compared to treatment as usual in The Netherlands. In The Netherlands, treatment as usual relies more frequently on in-home services, but also includes individual treatment, some combination of both or no services. The study included 256 adolescents [mean age: 16.02 (1.31) years; 73% male] randomly allocated to either MST or treatment as usual interventions. Researchers used the CBCL Aggression and Delinquency subscales to assess externalizing behaviors and delinquency. Parents also filled out several symptom scales from the Disruptive Behaviors Disorder rating scales. Adolescents self-reported using YSR and SRD assessments. According to both parent and youth self-reports, MST was significantly more effective at reducing externalizing behavior problems [CBCL baseline mean: 23.32 (12.60); CBCL end-of-treatment mean: 17.64 (11.57); change: 24% reduction] than treatment as usual [CBCL baseline mean: 22.55 (12.95); CBCL end-of-treatment mean: 19.25 (10.56); change: 15% reduction]. The YSR showed similar results, with a 16 percent reduction in the MST group and only a 3 percent reduction in the treatment as usual group. MST was also more effective at decreasing ODD and CD, as compared to treatment as usual. With regard to self-report of delinquent behaviors, MST demonstrated significant reductions for property offenses, but no significant effect was found for violent offending. Interestingly, further analysis of other secondary outcomes- such as parent and adolescent cognitions, parenting behavior and peer relationships- and demographic variables yielded unexpected results. While MST was equally effective across ages and ethnicity, the intervention showed larger effects for adolescent cognitions for boys than for girls. At 6-month post-treatment follow-up, there was evidence of sustained effects of MST in comparison to TAU with maintenance of statistically significant reductions in externalizing problems, ODD, and CD, but the number of re-arrests and time to re-arrest did not differ between the groups.171
Other Multicomponent Interventions
One RCT (moderate risk of bias)146 examined the effect of a semi-structured bibliotherapy intervention aimed to decrease aggressive behavior in youth (Table 28). The study was conducted in the Druze community in Israel, which is a closed society living in generally segregated cities or villages. Seventy-five children (77% male) were randomly and equally assigned to one of three conditions: child treatment only, mother plus child treatment and no treatment at all. The additional parent group was aimed at increasing parent's understanding of their child's aggressive behavior. Researchers measured aggression using a reduced version of the aggression and delinquency subscales of the CBCL questionnaire as reported by parents (CBCL), the adolescents (YSR), and their teachers (TRF). Another parent report, Coping with Children's Negative Emotions Scale (CCNS), was also used. Both treatment groups, the child group and the parent/child combination group, were more effective at reducing aggressive behavior than no treatment at all. However, the combined intervention was not significantly more effective at reducing disruptive behaviors than the child training only intervention. While obtained means demonstrated a greater decrease in aggressive behavior of the combined treatment intervention, significance was only found with the self-report measure, not with the parent or teacher report. Thus, the researchers' hypothesis of enhanced outcomes with the additional parent component was only partially supported.
A nonrandomized cohort study (high risk of bias)86 conducted in The Netherlands did not report positive treatment effect for disruptive behavior problems (Table 28). The study compared the effectiveness of treatments being offered in a forensic youth outpatient clinic at reducing recidivism. Treatments included functional family therapy (FFT) (n = 55), individual CBT (n = 87), and CBT combined with parent training (n = 50). In addition to these treatments, some youths also participated in Aggression Replacement Training (ART) (n = 27). It should be noted that both FFT and ART were implemented as trial versions and most implementing therapists had not been formally trained in administering these interventions. The official records of the 192 adolescents completing treatment in the outpatient clinic (mean age: 17.0 years; 85% male) were analyzed retrospectively, with occurrences of recidivism serving as the primary outcome measure. The study found no significant differences in 2-year total or violent recidivism rates between the different treatment interventions. However, researchers did find a higher recidivism rate for those youth who had additionally participated in ART (54% recidivism compared to 30% for non-ART juveniles), even after controlling for the type of offense committed (i.e. violent). There was also no significance found in recidivism between the treatment groups as compared to youth who dropped out of treatment (n = 42). The study found a significant interaction between moderating variables regarding patient characteristics (ethnicity), intensity and frequency of treatment, and the therapist conducting the training.
Bayesian Meta-Analysis of Psychosocial Interventions
Convergence diagnostics showed no evidence for lack of convergence in the 50,000 samples used for inference. Model fit was assessed using posterior predictive checks,173 which revealed no strong evidence of lack of fit.
To aid interpretation, the effect sizes estimated by our model can be interpreted as the expected change in score for the intervention category relative to treatment as usual or control, in standard deviation units (negative values are reductions in score). Thus, a value of −1 is an expected reduction in score of one standard deviation under the associated treatment. The effect size for the multicomponent interventions and interventions with only a parent component had the same estimated value (Figure 3), with a median of −1.2 standard deviations reduction in outcome score (95% credible intervals: −1.6 to −0.9). The estimate for interventions with only a child component was −1.0 (95% credible interval: −1.6 to −0.4).
Both the multicomponent intervention category and the interventions with only a parent component had the highest posterior probability (43%) of being the best intervention (defined as having the largest effect size), followed by interventions with only a child component (14%).
Age effects were relatively more subtle, with an additive median effect of −0.4 standard deviations (95% credible interval: −0.6 to −0.3) for preschool relative to school-age children (baseline level), and of −0.1 standard deviations (95% credible interval: −0.5 to 0.2) for adolescents relative to school-age children. These trends were evident across each of the outcome measures included in the analysis.
A summary of estimated overall treatment outcomes is shown in Figures 4-6 for each treatment class, as well as for control/treatment as usual. Results are presented separately for each included outcome measure and age group.
All three classes show shifts away from control/treatment as usual, though with high residual variability within class, and overlap among classes.
Random effect variances describe additional variation in the output beyond that accounted for by the factors included in the model. Mean estimates were 0.18 (SD: 0.034) (95% CI: 0.12 to 0.25) for ECBI Intensity score, 0.17 (SD: 0.038) (95% CI: 0.09 to 0.24) for ECBI Problem score, and 0.13 (SD: 0.027) (95% CI: 0.08 to 0.18) for CBCL Externalizing T score.
Using cut points greater than 127 for the ECBI Intensity scale, 11 for the ECBI Problem scale, and 60 for the CBCL Externalizing T-score,174,175 we estimated the marginal posterior probabilities of remaining above the cut point on each measure (Table 30). Remaining above the clinical cut point means that children continued to experience clinically significant symptoms. Posterior probabilities of remaining above the cut point are nominally higher for the treatment as usual/control group relative to each of the intervention groups, with multicomponent interventions showing the lowest proportion of children still above the clinical cut off post-treatment.
For example, this means that 95 percent of school-age children randomized to TAU/Control interventions, 66 percent of school-age children randomized to interventions with only a child component, 46 percent of school-age children randomized to interventions with only a parent component, and 47 percent of school-age children randomized to multicomponent interventions remained above the clinical ECBI Intensity Subscale clinical cutoff at the end of treatment. This suggests that multicomponent interventions are more effective. Similar trends were evident for the other age groups and outcome measures.
For the PCIT intervention, there was some uncertainty regarding whether it was most appropriately classified as a multicomponent intervention (as shown above) or as an intervention with only a parent component. We classified PCIT as a multicomponent intervention primarily because the focus of the intervention – as its name suggests – is on the parent-child interaction and includes the parent and child engaged together in activities. Thus, PCIT is arguably more similar to the family-based interventions included in our multi-component intervention category than it is to an intervention that only includes parents (e.g., our category of interventions that only include a parent component).
Nevertheless, to address this concern, we ran the model under both classifications (i.e., with PCIT categorized as a multicomponent intervention (as shown above) and as an intervention with only a parent component (results not shown) to compare the resulting estimates). Classifying PCIT as an intervention with only a parent component did not significantly change our meta-analysis results, although point estimates of effect were nominally different.
Key Question 2. In children under 18 years of age treated for disruptive behaviors, are alpha-agonists, anticonvulsants, beta-blockers, central nervous system stimulants, first-generation antipsychotics, second-generation (atypical) antipsychotics, and selective serotonin reuptake inhibitors more effective for improving short-term and long-term psychosocial outcomes than placebo or other pharmacologic interventions?
Overview of the Literature for KQ2
This section presents results of studies meeting our review criteria and addressing the effectiveness of pharmacologic treatments for disruptive behavior. Thirteen studies176-188 (reported in 15 papers)176-190 of medical intervention met the criteria for inclusion. Medical studies fall into four major categories; antipsychotic, antiepileptic drugs, typically targeted to aggression in children,191 and a group of drugs comprising both stimulants and nonstimulants typically used in children with comorbid ADHD (Table 31). Three studies evaluated short-term quality of life outcomes. No studies were of drugs with an FDA indication for DBD.
Key Points for KQ2
- Thirteen studies (12 RCTs and 1 cohort study) evaluated pharmacologic treatment for DBDs. One RCT was assessed as low risk of bias; seven were assessed as moderate risk of bias, and four as high risk of bias. The one nonrandomized controlled study was assessed as high risk of bias.
- Almost all studies were wholly or partially funded by a pharmaceutical industry. One study was federally funded.
- The duration of studies was short, with a range of 4 to 10 weeks. One study assessed 6 months of maintenance therapy.
- Studies of antipsychotic medications had mixed results over the short term, including differences in clinician versus parent rated outcomes within the same study.
- Valproic acid, an antiepileptic, also showed mixed results in RCTs, with one placebo-controlled study favoring the intervention, and another study demonstrating no significant difference. In one dosing study, higher doses were associated with greater effectiveness than lower doses.
- In one high risk of bias RCT, stimulants were associated with significant improvements in the ODD subscore of the parent-rated SNAP-IV for children and adolescents with ODD who were treated with mixed amphetamine salts extended release at doses of 30 mg/day over 5 weeks compared to placebo; and in one RCT (high risk of bias), use of methylphenidate (up to 60 mg/day in 2 divided doses) over a 5-week period in a school-aged population with CD symptoms found both teacher and parent ratings of CD problems improved compared to placebo
- In studies of nonstimulant ADHD medications, two RCTs (1 high and 1 moderate risk of bias) reported that atomoxetine was more effective than placebo in significantly reducing ODD symptoms as measured by the Swanson, Nolan, and Pelham Rating Scale-Revised (SNAP-IV) ODD subscore. Results were maintained up to 9 weeks among school-aged children with comorbid ADHD and ODD.
- In one moderate risk of bias RCT, guanfacine extended release significantly reduced oppositional symptoms for up to 9 weeks as measured by the CPRS-R:L oppositional subscale scores compared with placebo among children with ADHD and comorbid ODD.
Detailed Analysis
Antipsychotics
We identified five studies that address the use of atypical antipsychotic medications for the treatment of DBDs (Table 32 and Table 33). The most well studied antipsychotic was risperidone, for which there were three RCTs.181,183,186 In addition, one study compared aripiprazole to ziprasidone188 and one study compared quetiapine to placebo.180 These studies were funded by the pharmaceutical company that markets the drug studied, except for the aripiprazole and ziprasidone study, for which funding was not specified, but in which all authors had served on the speaker bureau for those manufacturers.
Risperidone
Three studies compared risperidone to placebo, but under different circumstances.181,183,186 One compared initial risperidone treatment to placebo, one examined the role of risperidone as an augmentation to stimulant medication, and the third assessed the role of risperidone as maintenance treatment after initial risperidone treatment.
A low risk of bias RCT186 measured the effect of risperidone on aggression, as measured by the Ratings of Aggression Against People (RAAP) scale. This study was funded by a combination of NICHD funding and the Janssen Research Foundation, and received low risk of bias scored in all domains. Twenty participants were included with 10 randomized to each arm. The trial lasted 10 weeks and took place at a single U.S. academic medical center outpatient clinic. Participants included 19 male and one female, with a mean age of 9.2 years (range: 6 to 14 years, inclusive). The RAAP score difference from baseline over the final four weeks of the 10-week study was −0.7 for the placebo group and −1.91 for the risperidone group (p=0.0007). In addition, the Clinical Global Impressions-Severity (CGI-S) scale was used as a secondary outcome, and the change was significantly greater for the risperidone group compared to the placebo group (−2.46 vs. −1.06, p=0.01). The average number of tablets was 5.0 (0.4) for patients treated with placebo and 4.1 (0.3) for patients treated with risperidone.
The study of risperidone as augmentation to stimulant was also an RCT (moderate risk of bias).181 Twenty-five children between the ages of 7 and 12, mostly male (22/25) and with a co-diagnosis of ADHD and symptoms of aggression, were included. The primary measures of aggression were the Children's Aggression Scale, parent (CAS-P) and teacher (CAS-T) versions. Mean dose by the end of the 4-week study was 1.08 mg/day for the risperidone group and 1.04 mg/day for placebo. No significant differences in effect were observed on either version of the CAS or the Clinical Global Impressions (CGI).
Finally, a large multicenter RCT (high risk of bias) examined the role of risperidone as maintenance treatment after an initial 12-week treatment period.183 Participants were primarily boys, ages 5 to 17 (n = 335) and were randomized to 6 months of risperidone or placebo after an initial 12 weeks of treatment with risperidone. Eligible patients had a DSM-IV diagnosis of conduct disorder, ODD, or DBD, not otherwise specified. Outcomes were assessed using the Nisonger Child Behavior rating form, the CGI and CGAS. The study was conducted from 2011-2003 in seven countries in Europe and one country in Africa (S. Africa). During the 6-month maintenance phase of the study, the average risperidone dose was 0.81 mg/day for children less than 50kg and 1.22 mg/day for children who weighed greater than or equal to 50 kg. At the end of the study, Nisonger Child Behavior Rating Form score for Conduct problems increased (worsened) from the end of the acute phase by 5.0 (9.5) points in the risperidone group (n = 172) and by 8.8 (11.2) points in the placebo group (n = 163). The CGI-S increased (worsened) by 0.6 (1.2) in the risperidone group and 1.2 (1.4) in the placebo group. The CGAS decreased (worsened) by 3.5 (12.4) points in the risperidone group and 10.2 (14.5) points in the placebo group. All differences were statistically significant (p<0.001). However, this study is challenged by high attrition, with only 58 percent (100/172) of the treatment group and 38 percent (62/163) of the placebo group completing. Overall, there was little difference between risperidone and placebo in the maintenance treatment.
Aripiprazole Versus Ziprasidone
One nonrandomized, open trial (high risk of bias)188 measured the difference in effect between aripiprazole and ziprasidone on aggression ratings in a sample of 46 mostly male (36/46) patients between the ages of 6 and 18 at an American outpatient clinic. Patients were eligible for inclusion if they demonstrated clinically significant aggressive behavior, deemed severe enough to warrant pharmacotherapy. Measurements were taken at baseline and after two months of treatment. Participants in both groups had reductions in their scores on the Overt Aggression Scale (OAS). Across groups there was a reduction among completers from 7.1 (1.9) to 2.6 (2.5). There was no difference in effect between the groups. The aripiprazole group had a mean decrease of 4.5 points on the OAS and the ziprasidone group had a mean decrease of 4.3 points on the OAS.
Quetiapine Versus Placebo
One randomized, controlled trial (moderate risk of bias)180 compared the efficacy of quetiapine versus placebo for reducing aggression, assessed via the parent-rated OAS and clinician-rated CGI. Additional measures were the parent-rated Conners Parent Rating Scale (CPRS) and Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q). Study participants met criteria for a primary diagnosis of conduct disorder and were documented to have moderate-to-severe aggressive behavior (OAS score ≥ 25) and at least moderate severity of symptoms (CGI-S score ≥ 4).
The study was conducted at a single academic medical center in the United States. Nine patients were randomized to receive quetiapine, and 10 were randomized to receive placebo. Patients were between the ages of 12 and 17, inclusive and were mostly male (14/19). The patients were recruited from a single site and the trial lasted for 7 weeks, including 6 weeks of quetiapine versus placebo. At the end of the study, the average (SD) daily dose of quetiapine was 294 (78) mg. While no difference was observed on the OAS (rated by parents), there was a significant difference in outcomes measured by the CGI (rated by clinicians). The quetiapine group average CGI score fell from 5.9 to 3.4 over six weeks and the placebo group fell from 5.5 to 5.0, for a difference between groups of 1.8 (95% CI: −0.53 to −3.1). The additional measures were CPRS (no significant difference) and Q-LES-Q, which showed an improved quality of life rating for the parents of the children in the quetiapine group (11.3 units) compared with a decrease of 4.1 units in the placebo group (p=0.005). Overall, the results were mixed regarding difference between quetiapine and placebo.
Antiepileptics
Valproic Acid
We identified two independent studies and one related pair of studies that addressed the use of valproic acid in the treatment of disruptive behavior in children (Table 34).178,184,185,189 These studies were funded by the drug manufacturer, Abbott pharmaceuticals, except for one,185 which was funded by a grant from the National Institute of Drug Abuse.
Valproic Acid Versus Placebo
One randomized, placebo-controlled study (moderate risk of bias)178 measured the effect of valproic acid in reducing aggressive behavior in younger children, from ages 6 to 13 years, with 21 of 27 males, who had aggression persisting after a trial of stimulant medications. Thirty patients were randomized to add-on valproic acid or placebo adjunctive to stimulant medication for eight weeks. The study participants were boys (n = 21) and girls (n = 6) with a diagnosis of ADHD and a co-diagnosis of either ODD or CD. Enrollment occurred between 2004 and 2007 at two academic medical centers in the United States. The mean daily dose of children in the valproic acid group was 567 mg/day (mean serum level: 68.11 mg/liter) and the children assigned to the placebo group had a drug equivalent dose of 685 mg.
The primary outcome was scoring on the Retrospective-Modified Overt Aggression Scale (R-M OAS). Thirteen patients in the placebo group and 14 patients in the valproic acid group were analyzed due to withdrawal prior to first assessment. The scores on the R-M OAS dropped from 41.80 to 32.13 in the valproic acid group and from 53.31 to 35.77 in the placebo group, with no significant difference between groups.
Another placebo-controlled crossover RCT (moderate risk of bias)185 included children and adolescents, ages 10 to 18, mostly male (16/20) with conduct disorder or oppositional defiant disorder. The study was conducted at an outpatient clinic at an academic medical center in the United States. A blinded assessor rated the modified OAS and the SCL-90 Anger Hostility items. Response was measured as greater than or equal to 70 percent decrease from baseline in the combined scores of these items. The final dose of valproic acid ranged from 750 to 1500 mg per day. In the first 6-week phase of the study, 10 patients were randomized to the valproic acid arm and eight patients responded. None of the 10 patients randomized to the placebo arm responded.
During the second 6-week phase of the study, the participants crossed over to the alternate intervention; six of seven nonresponders to placebo in the initial phase achieved response in the treatment phase. Of the eight who switched from the treatment group to placebo in phase 2, all of whom had responded in phase 1, six relapsed.
High Dose Versus Low Dose Valproic Acid
One moderate risk of bias randomized, placebo-controlled study (reported in two publications)184,189 measured the effect of valproic acid on a group of adolescent male patients with a diagnosis of conduct disorder from a correctional facility in California. The trial was 7 weeks long with 6 weeks of active treatment. Data were analyzed from 58 completers, all of whom had at least one offense “against persons.” The study included a (blinded) clinician-reported CGI. In the high dose group (mode=1000 mg/day, n = 34), 53 percent were “very much or much improved,” 29 percent were “minimally improved” and 18 percent were “no change or minimally worse.” In the low dose group (mode=125 mg/day, n = 24) 8 percent were “very much or much improved,” 42 percent were “minimally improved” and 50 percent were “no change or minimally worse.” The second paper of this family189 focused on the difference between treatment with high or low dose valproic acid on High Distress Conduct Disorder (HDCD) and Low Distress Conduct Disorder (LDCD). In the high dose group, 25 were identified as HDCD and nine with LDCD. Of those with HDCD on high dose valproic acid, 16 showed a response as measured by CGI-I (defined as improved, much improved or very much improved) and nine showed no response (defined as No Response). Of those with HDCD on low dose valproic acid, two were responders and 14 showed no response. Of those with LDCD on high dose valproic acid, two were responders and seven showed no response. Of those with LDCD on low dose valproic acid, none showed response and eight showed no response. Overall, valproic acid appeared more effective at high dose than low dose, and more effective in the HDCD group than the LDCD group.
Overview of Medications Commonly Used To Treat ADHD
A number of drugs typically used to treat ADHD are also used in the treatment of disruptive behaviors, most often with children who have comorbid ADHD and DBD. They fall into two primary classes: stimulants and nonstimulants.
We identified two studies that evaluated the use of stimulants: methylphenidate187 and mixed amphetamine salts extended release.182 We identified three studies (reported in 4 papers) that addressed the use of pharmacologic agents that are nonstimulants: selective norepinephrine reuptake inhibitor atomoxetine176,179,190 and the central alpha2A-adrenergic receptor agonist guanfacine.177 All five studies were RCTs and were conducted in Germany,176 Italy,179 and the United States.177,182,187 We rated two as moderate risk of bias, and three as high risk of bias. All studies were conducted among school-aged children (range: 6 to 17 years of age).
All studies provided definitions for ODD/CD/DBD, however, most included populations with comorbid ADHD. For the nonstimulant ADHD medications, the two RCTs of atomoxetine176,179 (reported in 3 papers176,179,190) studied children with ADHD and comorbid ODD, as defined by the DSM-IV-TR. One RCT of guanfacine studied children with ADHD defined by DSM-IV-TR and oppositional symptoms according to the subscale of the Conners Parent rating Scale Long form (CPRS-R:L).”177 For the ADHD stimulant medications, the RCT of methylphenidate187 used DSM-III criteria for CD with slight modification where two-thirds had comorbid ADHD, as defined by DSM-IV criteria. The RCT of amphetamine182 included children with ODD as defined by DSM-IV-TR, 79 percent had comorbid ADHD.
Outcomes efficacy measures for ODD symptoms included either the SNAP-IV ODD subscore or the oppositional subscore of the Conners Parent rating scale. Two papers also reported quality of life.179,190 The duration of studies was short, ranging from 4 to 9 weeks. Three of the studies were industry sponsored.176,179,182
Stimulants Overview
Two studies, one industry-funded182 and one funded in part by the National Institute of Mental Health,187 assessed as high risk of bias evaluated the use of two different stimulant medications (amphetamine, methylphenidate) among children with DBD (Table 35).
The first was conducted in the United States and evaluated four different doses of mixed amphetamine salts extended release compared to placebo over a 4-week period among children and adolescents aged 6 to 17 years with ODD as defined by DSM-IV-TR.182 Most (79%) had comorbid ADHD; however, results were not presented separately for this subgroup. The mean age of patients was 10.6 years among those who received mixed amphetamine salts extended release and 10.5 years in the placebo group; 69 percent were male. Significant improvements were observed in the ODD subscale of the SNAP-IV parent rating for doses of 30 mg/day (least squares mean difference from baseline: −0.43) compared to placebo (p<0.005).
One RCT (high risk of bias) also conducted in the United States evaluated use of methylphenidate (up to 60 mg/day in 2 divided doses) compared to placebo over a 5-week period among a school-aged population with CD symptoms.187 Criteria for CD were defined by DSM-III with slight modification; two-thirds of the population had comorbid ADHD, as defined by DSM-IV. The mean age was 10.2 years in the treatment group and 10.2 years in placebo with 88 and 90 percent proportion of males, respectively. Results found both teacher and parent ratings of CD problems improved compared to placebo.
Amphetamine Salts (Adderall)
One high risk of bias multicenter, randomized, double blind, placebo-controlled study examined the efficacy and safety of mixed amphetamine salts extended release for the treatment of children and adolescents with ODD.182 Children and adolescents with ODD (n = 308) were randomized 1:1:1:1 to receive active treatment with mixed amphetamine salts extended release 10 mg/day (n = 60), 20 mg/day (n = 58), 30 mg/day (n = 69), or 40 mg/day (n = 61) or placebo (n = 60) for 4 weeks with forced dose escalation after a washout period. Eligible participants were aged 6 to 17 years with ODD as defined by DSM-IV-TR. Patients with conduct disorder were excluded. The primary outcome was the ODD subscale of the SNAP-IV parent rating. Secondary outcomes include the ODD subscale of the SNAP-IV teacher ratings, ADHD subscales of the SNAP-IV parent and teacher ratings, the child health questionnaire parent form 50 (CHQ-PF50) and adverse events. A total of 244 patients (79.2%) had comorbid ADHD, however results were not presented among this subgroup. The mean baseline score for the ODD subscale of the SNAP-IV parent rating did not differ by treatment group. In the intention-to-treat population, statistically significant improvements in oppositional symptoms as measured by the parent-rated SNAP-IV ODD subscale were observed in the least squares mean difference (−0.43) for those in the higher dose (30 mg/day) group compared with the placebo group (p<0.005). Statistically significant improvements for the teacher rated ODD subscale of the SNAP-IV from baseline to endpoint was seen in the intention-to-treat populations who received mixed amphetamine salts extended release 10 mg/day (p=0.047), 20 mg/day (p=0.043), and 30 mg/day (p=0.003), compared to placebo group. Mixed amphetamine salts extended release was associated with improvement in quality of life outcomes, measured with the CHQ, including statistically significant improvements in behavior, physical and psychosocial summary for those in the mixed amphetamine salts extended release 30 and 40 mg/day groups compared to placebo; and for self-esteem in the mixed amphetamine salts extended release 40 mg/day group compared to placebo. When stratified by baseline symptoms in a post hoc reanalysis of the per protocol population, mean changes from baseline in the ODD subscore of the parent rated SNAP-IV was greater for the high baseline ODD severity group.
Methylphenidate (Ritalin)
The second stimulant study that we identified compared methylphenidate to placebo in an RCT including 83 children and adolescents with CD.187 Participants received methylphenidate (n = 41) or placebo (n = 42) for 5 weeks with a maximum dose of 60 mg per day in two divided doses to evaluate symptoms of CD. Eligible participants were 6 to 15 years of age and met DSM-II criteria for CD, which were slightly modified; moderate to severe impairment rating by teacher or parents, and an IQ greater than 70. DSM-IV criteria were used to diagnose ADHD. Primary outcomes were parent and teacher ratings of CD symptoms based on the Conners Teacher Rating Scale, and subscales of the Quay revised behavior problem checklist, and global estimates of the severity of behavioral problems. Participants mean age was 10.2 (2.3) years in the methylphenidate group and 10.2 (2.5) years in the placebo group. All but two children had at least three symptoms of CD, consistent with DSM-IV criteria; 69 percent of the population also met DSM-IV criteria for ADHD, however, results were given for the entire sample and not by those with comorbid ADHD separately. Baseline teacher overall rating for conduct problems was 2.6 (0.7). Teacher rated overall conduct problems were significantly less for those children taking methylphenidate [1.3 (0.1)] compared to placebo [2.3 (0.1), p<0.001] and factor scores including aggression, conduct problems, and conduct disorder were significantly improved compared to placebo. Teacher ratings of ADHD symptoms were also significantly improved among those who received methylphenidate compared to placebo. Significant improvements on parent ratings of aggression, conduct problems, and conduct disorder were seen in the methylphenidate group compared to placebo. Socialized aggression showed no statistical improvement on either the parent or the teacher ratings. Among 47 elementary school-aged children, classroom observers' ratings showed significant improvements among methylphenidate compared to placebo groups with regards to global rating of conduct problem severity and aggression (Iowa scale).
Nonstimulants
Three studies176,177,179 reported in four publications176,177,179,190 evaluated the efficacy of nonstimulants on oppositional symptoms among children with ADHD and ODD symptoms (Table 36). All were RCTs and were conducted in Germany, Italy, and the United States. We assessed risk of bias as moderate in two studies176,177 and high in one study.179 All were conducted among school-aged children (range 6 to 17 years of age).
Two RCTs176,179 addressed the use of atomoxetine in children with ADHD and comorbid ODD/CD. Atomoxetine is a centrally acting, norepinephrine reuptake inhibitor with minimal affinity for other neurotransmitter receptors. Atomoxetine was approved by the FDA for treatment of ADHD in children, adolescents, and adults in 2002.192 These two RCTs were designed specifically to examine the effects of treatment on oppositional symptoms in children with ADHD and comorbid ODD defined by the DSM-IV-TR. The RCTs included 226 participants in treatment arms, and 91 participants in placebo arms. Participants had an average age of 10.9 and 9.7 years in the treatment groups and 11.1 and 10.0 years in the placebo groups of each trial, respectively. More male subjects were included in both treatment (86%, 93%) and placebo groups (81%, 91%) of each trial, respectively. Both trials evaluated doses titrated up to 1.2 mg per kg per day.
Outcome efficacy measures for ODD symptoms were from the SNAP-IV ODD subscore. Mean (SD) baseline SNAP-IV ODD sub-scores were 15.5 (4.4) and 17.2 (NR) in treatment groups and 15.6 (5.1) and 17.5 (NR) in placebo groups for the 2011176 and 2009179 studies, respectively. Both RCTs reported significant improvements in ODD symptoms, as measured by either the SNAP-IV ODD subscale or the Conners Parent rating Scale Long (CPRS-R:L) over an 8- to 9-week period. One study176 reported significant improvement in quality of life in a separate publication190 and one study179 found no significant differences in overall quality of life scores over the 8-week period but did find improvements in certain subdomains (risk avoidance, emotional comfort).
We identified one study that evaluated the use of the nonstimulant guanfacine extended release (1-4 mg/day) in children with ADHD and comorbid ODD.177 ADHD was defined by the DSM-IV-TR and oppositional symptoms according to the subscale of the CPRS-R:L form. Guanfacine extended release is a selective central alpha2A-adrenergic receptor agonist indicated for the treatment of ADHD in children ages 6 to 17 years as monotherapy and as adjunctive therapy to stimulant medication. Guanfacine extended release significantly reduced oppositional symptoms as measured by the CPRS-R:L oppositional subscale scores compared with placebo. The duration of all three studies was short, ranging from 8 to 9 weeks. All of the studies were industry sponsored.
Atomoxetine
A moderate risk of bias randomized, double-blind, placebo-controlled, three-arm, multicenter study was conducted in 20 sites in Germany to assess the efficacy of atomoxetine given once daily for 9 weeks (target dose: 1.2 mg/kg/day), using either fast or slow titration, for treating symptoms of ODD in children and adolescents with ADHD and comorbid ODD/CD.176 Eligible participants were aged 6 to 17 years and met the DSM-IV-TR criteria for ADHD (any subtype) and DSM-IV criteria A through C for ODD; DSM-IV-TR criteria for CD was not an exclusion. Only outpatients were enrolled from primary and secondary sites. Participants were randomized to one of three arms: (1) atomoxetine 0.5 mg/kg/day for 7 days followed by the target dose of 1.2 mg/kg (atomoxetine fast titrating group, n = 60); (2) atomoxetine 0.5 mg/kg/day for 7 days, followed by 0.8 mg/kg/day for 7 days, followed by target does of 1.2 mg/kg/day (atomoxetine-slow titrating group, n = 61); or (3) placebo (n = 59) for nine weeks, after a 3- to 28-day screening and washout period. The primary outcome was the investigator-rated SNAP-IV ODD subscale score. Other outcomes included the SNAP-IV ADHD subscale score and adverse events. Baseline characteristics were comparable for the three groups [84% male, mean age: 11 (3) years]. Participants DBD comorbidity was 74 percent (n = 134) ODD, 24 percent (n = 44) CD, with one patient meeting criteria for DBD, not otherwise specified and one for adjustment disorder. Baseline mean overall SNAP-IV ODD scores were 15.5 (4.35). Using a mixed effects model for repeated measures, treatment with atomoxetine once daily for nine weeks, pooling fast and slow titration arms, significantly reduced ODD symptoms compared to placebo, as measured by the SNAP-IV ODD score, least square mean treatment group difference at week 9, atomoxetine-pooled minus placebo: −3.2 (95% CI: −5.0 to −1.5), effect size: −0.69, p<0.001. The decrease in ODD symptoms was significant for both the fast and slow titration groups, (least square mean, atomoxetine-fast 8.6 (95% CI: 7.2, 9.9), atomoxetine-slow 9.0 (95% CI: 7.7, 10.3) compared to placebo 12.0 (95% CI: 10.6, 13.5), p<0.001, effects size −0.74 and p=0.003, effect size −0.65, respectively). SNAP-IV ODD scores improved at least 30 percent in 48.3 percent of patients in the atomoxetine fast titration group compared with 55.7 percent in the atomoxetine slow titration group and 35.6 percent in the placebo group. There were no significant differences between the atomoxetine fast and atomoxetine slow titration groups. Atomoxetine significantly reduced ADHD symptoms compared to placebo at week 9 as measured by the SNAP-IV ADHD subscale score. Patients in the atomoxetine slow titration group stayed on treatment significantly longer than did patients in the placebo group (HR=3.57; 95% CI: 1.42 to 8.94, p=0.007). Study was sponsored by industry.
A second paper in the family of studies evaluated the outcome of quality of life in the same 9-week trial of atomoxetine (target dose 1.2 mg/kg/day) versus placebo.190 Quality of life was measured using the parent rated KINDL-R questionnaire total scores and sub-scores on emotional well-bring, self- esteem, friends, family, school, and physical well- being, a validated instrument. Family burden of illness was measured using the parent rated FaBel questionnaire, a German version of the Impact on Family Scale. At baseline, the mean overall KINDL-R scores were 62.9 (12.78) and the mean overall FaBel score were 53.8 (12.89). Among those treated with atomoxetine, the KINDL-R total score increased significantly compared to those in the placebo group, (mean change: 2.6 vs. −1.6 points) ANCOVA LS-mean difference, atomoxetine pooled minus placebo: 5.0 (0.8, 9.3), effect size: 0.377, p=0.021), which was clinically relevant. There was no significant difference between the fast and slow titration groups in KINDL total or subscores. Quality of life subscores for emotional well- being, self-esteem, family, and friends increased significantly in patients treated with atomoxetine compared to placebo. There were no statistically significant differences in the KINDL-R school subscore; however the subscore on physical wellbeing was significantly worse for patients in the atomoxetine group compared to placebo. Authors felt the physical wellbeing subscore differences may be related to common treatment adverse effects. No significant treatment effects were seen on family burden, as measured by the FaBel total score. However, the FaBel impact on siblings subscore improved significantly more in the atomoxetine group compared to placebo.
Finally, a multicenter, double blind, placebo-controlled trial (high risk of bias) conducted in Italy evaluated the efficacy of atomoxetine over 8 weeks in improving ADHD and ODD symptoms in children and adolescents with ADHD and comorbid ODD who had been non-responders to a previous parent support intervention.179 Eligible participants were 6 to 15 years of age, who were diagnosed with ADHD and ODD according to DSM-IV criteria, and were required to have a score of at least 1.5 SD above the age norm for the ADHD subscale of the SNAP-IV, a CGI-S score of four or higher at screening and baseline, a SNAP-IV ODD subscale score of at least 15, and a normal intelligence score. All patients were provided open-label, parent support for 6 weeks. Patients who did not respond to the parent support phase (response was defined as an improvement in CGI-S score of 2 or more from baseline and at least a 30 percent decrease from baseline in ADHD sub-score of SNAP-IV) were randomized 3:1 to atomoxetine (n = 105) or placebo (n = 32) once daily for 8 weeks.
The atomoxetine dose was titrated from 0.5 mg/kg/day to a target dose of 1.2 mg/kg/day in 7 days. The primary efficacy measure was the ADHD subscale score of the SNAP-IV; the ODD subscale score of the SNAP-IV was a secondary outcome. Other outcome measures included health related quality of life as measured by means of the parent-rated child health and illness profile-child edition (CHIP-CE), and adverse events. Of the 156 patients who participated in the parent support phase, 139 were randomized and 137 were included in the efficacy analysis. Participants mean age was 9.7 (2.2) years in the atomoxetine arm and 10.0 (2.4) years in the placebo arm; 93 percent were males.
Mean baseline SNAP-IV ODD score was 17.5 for atomoxetine and 17.2 in the placebo arm. At the end of 8 week period the SNAP-IV ODD sub score significantly improved in the atomoxetine group compared to placebo [SNAP-IV ODD subscale score mean change: −2.7 (4.1) in the atomoxetine arm vs. −0.3 (2.6) in placebo arm, p=0.0001]. There was significant decrease in the ADHD subscale of the SNAP-IV in the atomoxetine arm compared to placebo. There was no significant differences between the mean changes of the CHIP-CE total score between atomoxetine (3.6) and placebo (1.2), p=0.071; however the atomoxetine group showed statistically significant differences compared to placebo for the subdomains of risk avoidance (p=0.013) and emotional comfort (p=0.007). The study was sponsored by industry.
Guanfacine (Intuniv)
A moderate risk of bias multicenter randomized, double blind, placebo-controlled trial conducted in the United States randomized children and adolescents with ADHD and oppositional symptoms 2:1 to receive either guanfacine extended release (n = 138) or placebo (n = 79) once daily for 8 weeks.177 Eligible participants were between 6 and 12 years of age and had a DSM-IV-TR diagnosis of ADHD, a baseline score 24 or higher on the ADHD Rating Scale IV, and a baseline score 14 or higher (males) or 12 or higher (females) on the oppositional subscale of the CPRS-R:L. Following a 3-day to 5-week washout, participants underwent a 5-week dose optimization. During optimization, the dose of guanfacine extended release was increased in 1 mg/week increments to a maximum of 5 mg/day based on tolerance, the CGI-S score, and investigator judgment until the optimal dose was identified. Doses were maintained at the optimal level for 3 weeks. The primary outcome was change from baseline to endpoint in the oppositional subscale of the CPRS-R:L. Other outcomes included ADHD-RS-IV criteria, and adverse events. Participant mean age was 9.4 (1.7) years in the guanfacine extended release group and 9.3 (2.0) years in the placebo group. Mean score at baseline on the oppositional subscale of CPRS-R:L was 19.3 (4.74) in the guanfacine extended release group and 19.9 (4.29) in the placebo arm. Distribution of the optimal dose at the endpoint was: 1 mg (5.1%), 2 mg (27.2%), 3 mg (38.2%), and 4 mg (25%).
Guanfacine extended release significantly reduced oppositional symptoms as measured by the parent-rated CPRS-R:L oppositional subscale scores compared with placebo (least-square mean change from baseline: −10.9 for guanfacine extended release and −6.8 for placebo, p<0.001; effect size: 0.59) Least squares mean percentage reductions from baseline were significantly different between guanfacine extended release (56.3%) and placebo (33.4%) groups (effect size: 0.64, p<0.001). Significant reductions were observed in clinician-rated ADHD-RS-IV total scores in those treated with guanfacine extended release compared with placebo.
Key Question 3. In children under 18 years of age treated for disruptive behaviors, what is the relative effectiveness of any psychosocial interventions compared with the pharmacologic interventions listed in Key Question 2 for improving short-term and long-term psychosocial outcomes?
We identified no studies that directly compared psychosocial to pharmacologic interventions for DBD.
Key Question 4. In children under 18 years of age treated for disruptive behaviors, are any combined psychosocial and pharmacologic interventions listed in Key Question 2 more effective for improving short-term and long-term psychosocial outcomes than individual interventions?
We identified no studies assessing the comparative effectiveness of combination interventions.
Key Question 5. What are the harms associated with treating children under 18 years of age for disruptive behaviors with either psychosocial or pharmacologic interventions?
Overview of the Literature for KQ5
Harms for psychosocial interventions were not reported in studies included in KQ1. It is important to note that the absence of data on harms does not mean that harms are not present, even for psychosocial interventions. To represent the potential harms of the drugs used to treat disruptive behaviors in children, we combine data from three sources: 1) prior systematic reviews focused on harms of drugs; 2) empirical data from studies meeting our inclusion criteria for harms assessments; and 3) package insert data available from FDA (briefly summarized here and in more detail in Appendix I).
For each drug class we first summarize existing reviews, then describe the available empirical data from the literature search, and finally present the analysis of harms data gathered from the available gray literature (i.e., package inserts and FDA review packages). Sixteen studies176-188,193-195 (reported in 18 papers)176-188,193-197 of medical intervention met the criteria for inclusion and are described below. We included information from three systematic reviews.
The Package Insert Data sections provide an overview of the common and notable adverse events of each medication. When possible, adverse event data specifically from pediatric patients have been included but it should be noted that studies used to develop package inserts were not, of course, limited to the clinical population of interest in this review. Appendix I includes the pediatric indication for medications referenced in the clinical studies included in this review.
For the drug studies, it is important to note that these data often include children using the medications to treat disruptive behaviors and/or other (non-DBD) medical conditions. We summarize the rate of discontinuation due to adverse events as reported in the published studies in Table 37.
Second-Generation Antipsychotics
Risperidone
Key Points
- Studies were generally short-term with the exception of one trial with a 6-month treatment period. Duration of followup post-treatment was minimal in all studies.
- Adverse events were generally considered mild across studies, with weight gain, sedation, and somnolence frequently reported.
Overview
Use of risperidone, a second-generation antipsychotic, for management of disruptive behavior disorders was documented in a limited number of studies (n = 5).181,183,186,194-196 We rated two RCTs as good quality for harms reporting,181,186 two as fair,183,195,196 and one prospective cohort study as good quality for harms reporting.
Systematic Reviews
We identified three good quality systematic reviews addressing harms of atypical antipsychotics in children and adolescents.49,52,198
One Cochrane review assessed atypical antipsychotic use in individuals aged 18 years and younger diagnosed with a DBD.49 Seven of the eight RCTs identified addressed risperidone compared with placebo, and one evaluated quetiapine (summarized below). The primary harms assessed in the review were weight gain and changes in metabolic parameters. Sample sizes in RCTs of risperidone ranged from 13 to 335 (4 studies had 25 or fewer participants), and the review included three of the studies addressed in the current report.181,186 Mean doses at end of treatment ranged from 0.98 mg per day to 1.5 mg per day. Mean weight gain in the risperidone group was 2.37 kg more than in the placebo arm over 6 to 10 weeks in a meta-analysis of two trials (mean difference: 2.37, 95% CI: 0.26 to 4.49). Only one study evaluated metabolic changes and reported no clinically significant changes in mean fasting glucose levels during treatment. The investigators considered the overall quality of the evidence addressing these harms to be low.
Another Agency for Healthcare Research and Quality (AHRQ) review included studies of atypical antipsychotics used for any indication in individuals aged 24 years of age and younger.52 Agents included in studies in the review were haloperidol, risperidone, aripiprazole, olanzapine, pimozide, quetiapine, clozapine, and ziprasidone, and median study duration was 8 weeks. The review evaluated harms by drug class and noted fewer extrapyramidal symptoms associated with olanzapine and risperidone compared with haloperidol (low strength of the evidence), and no significant differences between first and second-generation antipsychotics in prolactin-related adverse events (low strength of the evidence). Risperidone was associated with less dyslipidemia and less weight gain than olanzapine (moderate strength of the evidence). Risperidone was also associated with more prolactin-related harms than olanzapine (moderate strength of the evidence) and with more weight gain than aripiprazole (low strength of the evidence).
Finally, one review and meta-analysis evaluated metabolic and neurologic adverse events associated with second-generation antipsychotic use in children with any mental health disorder and included 35 RCTs (4 reported in the current review).198 In a meta-analysis of 10 RCTs of risperidone of less than 12 weeks duration, weight gain (mean difference: 1.72 kg, 95% CI: 1.17 to 2.26, p<0.00001), prolactin levels (mean difference: 20.70 ng/mL, 95% CI: 16.78 to 24.62, p<0.00001), and change in prolactin from baseline to end of treatment (mean difference: 44.57 ng/mL, 95% CI: 32.24 to 56.90, p<0.00001) were higher in risperidone groups compared with placebo. The odds of clinically significant weight gain were higher in the risperidone arm compared with placebo (OR=2.90, p=NS) as were the odds of extrapyramidal symptoms (OR=3.35, p<0.0001) in the risperidone arm compared with placebo. The review reported no clinically significant changes in laboratory values or blood pressure in seven studies. Blood pressure was elevated in the risperidone group in one study. Olanzapine was associated with greater weight gain than was risperidone in a meta-analysis of two studies (mean difference: 2.41 kg, 95% CI: 0.98 to 3.83, p=0.0009) and with greater BMI change (mean difference: 0.09 kg/m2, 95% CI: 0.42 to 1.38, p=0.0003). In studies comparing risperidone at different doses or with other agents (pimozide, clonidine, haloperidol), children in the risperidone arms had weight gain and extrapyramidal symptoms that were typically not significantly different from the comparison group, though higher doses of risperidone were associated with greater weight gain and movement symptoms. In a meta-analysis of three RCTs of risperidone versus placebo of more than 12 weeks duration, mean weight gain was higher in risperidone groups compared with placebo (mean difference: 1.95 kg, 95% CI: 1.14 to 2.75, p<0.00001). Prolactin levels were higher in the risperidone group versus placebo (p<0.001) in one study, as were the odds of extrapyramidal symptoms (OR=3.71, p=NS). The review suggested that risk of metabolic adverse effects is greatest for olanzapine followed by clozapine and quetiapine, while risks were lower for risperidone and aripiprazole. The risk for neurologic harms appeared greatest with risperidone, olanzapine, and aripiprazole.198
Summary of Studies Reporting Harms Data
One randomized, double blind, placebo-controlled trial (Reyes 2006) assessed risperidone for maintenance treatment of children and adolescents (mean age: 11.1 years) with disruptive behavior disorders.183,196 Patients were eligible to enter the double blind, 6-month maintenance phase of this study after successful treatment with risperidone for a total of 12 weeks. Of the 527 patients who entered the 6-week, open-label, acute treatment phase, five patients did not continue due to adverse effects; in the six-week, single-blind, continuation treatment phase, seven patients discontinued due to adverse effects; finally, during the 6-month maintenance phase, four patients discontinued the study due to adverse effects. Specific adverse effects resulting in discontinuation of study drug were as follows: involuntary muscle contractions, abnormal ECG, paranoid reaction. By the conclusion of the 6-month maintenance phase, 47.7 percent of risperidone-treated patients and 36.2 percent of placebo-treated patients experienced at least one adverse event. The adverse events reported in 5 percent or more of patients are summarized in Table 38. Table 39 summarizes the incidence of extrapyramidal symptoms.
Another publication196 from the Reyes RCT183 evaluated the incidence of somnolence in a long-term analysis (6 months) of 284 5 to 17 year old children with DBD receiving risperidone (0.25 to 1.5 mg/day) or placebo.196 In the initial 6-week phase of the trial, 61 children reported somnolence, while in the 6-week open label phase, 10 participants had somnolence. During the double-blind maintenance phase, three children in the risperidone arm and three in the placebo arm reported somnolence, which was generally considered mild and likely related to risperidone in two of the children in the treatment arm and to placebo in one child in that arm. The mean (SD) duration of somnolence was 34.3 (42) days in the risperidone and 42.3 (50) days in the placebo arm.
Adverse events reported in a 12-week RCT of risperidone compared with placebo186 [n = 20 with CD or ODD, mean age: 9.2 (2.9) years] were generally mild and transient and included rash, increased appetite, sedation, headache, and irritability (Table 40). Predicted weight gain (based on repeated measures analysis) was greater in the risperidone group compared with placebo [4.2 (0.7) kg vs. 0.74 (0.9) kg, p=0.003]. No participants had dystonia and dyskinesia. One participant in the risperidone arm withdrew from the study due a rash that subsequently resolved. We rated this study as good quality for harms reporting.
Another short-term (8 weeks) RCT181 compared risperidone for treatment-resistant aggression in children with ADHD [n = 12, mean age: 7.3 (3.7) years] with placebo [n = 13, mean age: 8.8 (3.1) years].181 Nineteen children also had CD or ODD diagnoses, and 25 were receiving concomitant stimulants. More children in the placebo group (76.9%) reported an adverse event than in the risperidone group (58.3%, p=NR). Only abdominal pain and vomiting occurred in greater than 10 percent of participants in the risperidone group, while vomiting and somnolence occurred in more than 10 percent of the placebo arm. Weight gain did not differ significantly between groups, and laboratory values remained within normal limits in both groups. Investigators considered adverse events as mild in intensity, and no participants withdrew due to adverse events. Table 40 lists the harms reported by group. We considered this study as good quality for harms reporting.
In one fair quality, 8-week open label trial of risperidone [final dose, mean: 1.27 (0.42) mg/day] including 21 children with ODD or CD and ADHD [mean age: 10.8 (3.6) years], reported side effects were similarly mild.195 All children had initial mild sedation, and sleep duration increased by a mean of 0.9 hours on parental observation (range 0-3 hours). Mean weight gain was 1.6 (1.9) kilograms (mean 4% increase). Three participants gained more than 10 percent of their baseline body weight, and one gained approximately 29 percent. No participants developed EPS or had abnormal laboratory values.
One good quality analysis of data on participants (ages 4-19, mean 11.3 years) with ODD or CD enrolled in a cohort study of antipsychotic treatments reported specifically on metabolic adverse effects.194 Participants received antipsychotics either with stimulants (n = 82) or without stimulants (n = 71). Most of the 153 participants received either risperidone (33.3%) or aripiprazole (29.4%). The most commonly used stimulants were methylphenidate (13.1%) and D-Amphetamine (10.5%), and participants differed on multiple characteristics at baseline (ADHD comorbidity, use of stimulants prior to study, baseline weight at normal or below normal levels, waist circumference). In analyses controlling for baseline differences, changes in body composition, glucose and lipid parameters, and prolactin levels did not differ between groups, nor did discontinuation rates (4.2% in antipsychotics plus stimulant group vs. 7.4% in the antipsychotics alone arm).
Package Insert Data
Adverse event data for risperidone were gathered from the package insert and FDA approval packages for adolescent use.199 The other FDA review documents available did not include pediatric data.
Adverse events referenced in the warnings/precautions section of the package insert include: parkinsonism, akathisia, dystonia, tremor, sedation, dizziness, anxiety, blurred vision, nausea, vomiting, upper abdominal pain, stomach discomfort, dyspepsia, diarrhea, salivary hypersecretion, constipation, dry mouth, increased appetite, weight gain, fatigue, rash, nasal congestion, upper respiratory tract infection, nasopharyngitis, and pharyngolaryngeal pain. 199,200
When assessing the use of risperidone (0.5-6 mg/day) across all pediatric indications (i.e. schizophrenia, bipolar mania, autistic disorder), the mean change in fasting glucose from baseline was 2.6 mg/dL (n = 135), cholesterol was 0.3 mg/dL (n = 133), LDL was 0.5 mg/dL (n = 22), HDL was −1.9 mg/dL (n = 22), triglycerides was 2.6 mg/dL (n = 138), weight was 2 kg (n = 448), and weight gain (more than7% increase) was 32.6% (n = 448).199,201 Prolactin levels have also been shown to increase from baseline in pediatric patients taking risperidone; which appeared to be dose-dependent relationship.202 This increase has been shown to lead to prolactin-related adverse events such as: lactation nonpuerperal and ejaculation disorder.202 Common adverse events reported in long-term studies (greater than 6 months) included weight gain and psychosis.202 In general, extrapyramidal symptoms, dizziness, somnolence, and increasing salivation, and increased prolactin levels were considered dose-related.202
The sponsor conducted a literature search, which uncovered safety data from 206 articles in pediatric patients taking risperidone at doses between 0.25 and 12 mg/day or 0.01 and 0.06 mg/kg/day for up to 7 years.202 The most frequently reported adverse events were weight gain (75 articles), sedation (47 articles), and extrapyramidal symptoms (32 articles).202 The most common reasons for discontinuation in these articles included: weight gain (18 articles), extrapyramidal symptoms (11 articles), hyperprolactinemia (8 articles), and sedation (7 articles).202 Serious adverse events reported in 19 patients included: neuroleptic malignant syndrome (9), tardive dyskinesia (4), pancreatitis (2), acute dystonia (1), probably viral encephalitis (1), worsening mitochondrial disorder (1), and increased carbamazepine level (1).202
Common adverse events reported in pediatric patients with schizophrenia taking risperidone 1 to 3 mg/day (n = 55) for 6 weeks included: sedation (24%), parkinsonism (16%), tremor (11%), akathisia (9%), dizziness (7%), dystonia (2%), and anxiety (7%).199 In patients taking risperidone 4 to 6 mg/day (n = 51) for 6 weeks the following adverse events were reported: salivary hypersecretion (10%), sedation (12%), parkinsonism (28%), tremor (10%), akathisia (10%), dizziness (14%), dystonia (6%), and anxiety (6%).199,200
Patients taking risperidone (n = 106) in clinical trials discontinued treatment due to dizziness (2%), somnolence (1%), sedation (1%), lethargy (1%), anxiety (1%), balance disorder (1%), hypotension (1%), and palpitation (1%).199
Other Second-Generation Antipsychotics
Key Points
- Two small, short-term studies addressed quetiapine, aripiprazole, or ziprasidone.
- Adverse events were more frequent in the placebo arm in an RCT comparing quetiapine and placebo, and sedation was frequently reported in both arms in a study comparing aripiprazole and ziprasidone.
Overview of the Literature
Aripiprazole, ziprasidone, and quetiapine were used in the management of disruptive behavior disorders in two studies (1 good180 and 1 poor quality188 for harms) meeting our criteria.
Systematic Reviews
The good quality Cochrane review of atypical antipsychotics for DBD49 (described above) included one RCT of quetiapine180 (described in KQ2 above for effectiveness and below for harms). The Cochrane review addressed the adverse effects of weight gain and metabolic changes as primary outcomes and provided no significant analysis of the limited harms data in the study.
One AHRQ-funded review (described above) addressed atypical antipsychotics including quetiapine.52 The review reported that quetiapine was associated with significantly less weight gain than olanzapine (moderate strength of the evidence) but with more weight gain when compared with aripiprazole (low strength of the evidence). Quetiapine was also associated with more dyslipidemia than aripiprazole (low strength of the evidence). Aripiprazole was associated with fewer prolactin-related adverse events than placebo (moderate strength of the evidence), and differences between the effects of second generation antipsychotics related to extrapyramidal symptoms, insulin resistance, and sedation were not significant (low strength of the evidence).
Finally, one review and meta-analysis evaluated metabolic and neurologic adverse events associated with second-generation antipsychotic use in children with any mental health disorder. The review included 35 RCTs, four of which are in this review.198 In a meta-analysis of three studies of quetiapine versus placebo (including the RCT180 described below), weight gain but not prolactin levels was significantly higher in the quetiapine group (mean difference: 1.41 kg, 95% CI: 1.01 to 1.81). Triglyceride levels, blood pressure, and heart rate were significantly elevated in the quetiapine group compared with placebo in one RCT. The review also included nine RCTs assessing aripiprazole, five of which were combined in meta-analyses. Mean weight gain (mean difference: 0.85 kg, 95% CI: 0.57 to 1.13, p<0.00001) and BMI increase (mean difference: 0.27 kg/m2 95% CI: 0.11 to 0.42, p=0.0007) were higher in aripiprazole groups compared with placebo, and the odds of weight gain were significantly higher in the treatment group (OR=3.66, p=0.0003). Lipids and ECG values did not differ significantly between groups, and prolactin levels were significantly lower in treated participants versus those in placebo arms at endpoint (mean difference: −5.03 ng/mL, 95% CI: −7.80 to −2.26, p=0.0004). Participants receiving risperidone had greater odds of developing extrapyramidal symptoms compared with placebo (OR=3.70, p<0.00001). Studies included in the review did not report significant changes in blood pressure, heart rate, or laboratory values, and only one short-term study addressed ziprasidone. The review suggested that risks of metabolic adverse effects are greatest for olanzapine followed by clozapine and quetiapine, while risks were lower for risperidone and aripiprazole. The risk for neurologic harms appeared greatest with risperidone, olanzapine, and aripiprazole.
Summary of Studies Reporting Harms Data
One good quality, 7-week RCT (Connor 2008) compared quetiapine and placebo in children with CD and moderate-to-severe aggressive behavior (n = 19 [11 completers], mean age overall: 14.1 years).180 The mean number of parent-reported side effects and the mean severity did not differ significantly between groups nor did child-reported side effects including sedation, social withdrawal, and weight gain. Three adverse events were reported significantly more often by parents of children in the placebo arm compared with quetiapine: decreased mental alertness (n = 9 in placebo arm vs. n = 3 in quetiapine, p=0.01), diminished emotional expression (n = 7 in placebo arm vs. n = 1 in treatment, p=0.009), and diminished facial expression (n = 6 in placebo arm vs. n = 1 in treatment, p=0.03). Weight gain and prolactin levels did not differ significantly between groups, and laboratory parameters were in normal levels in both groups. Children in the quetiapine group had a higher resting pulse than did children in the placebo arm (p=0.01), and one child in the quetiapine group withdrew due to clinically noticeable akathisia. Table 41 lists harms reported by group.
In a poor quality, open label, nonrandomized study,188 investigators assessed harms following 8 weeks of either aripiprazole [n = 24, (20 completers)] or ziprasidone [n = 22 (14 completers)] in children (mean age: 11.9 years) with aggressive behavior.188 Use of stimulant medication was allowed (8% of the aripiprazole group; 36% of the ziprasidone group). Overall 71 percent of study completers experienced harms. Reported harms included sedation (n = 10 in aripiprazole arm vs. n = 8 in ziprasidone arm) and nausea and headaches (reported in 2 participants in each arm). Six children in the ziprasidone arm and two in the aripiprazole arm discontinued the study due to sedation. Table 41 lists harms reported by group.
Package Insert Data
Aripiprazole
The adverse event data for aripiprazole have been gathered from the package insert as well as FDA approval document for the pediatric schizophrenia indication.204 Adverse events referenced in the warnings/precautions section of the package insert include: neuroleptic malignant syndrome, tardive dyskinesia, hyperglycemia/diabetes mellitus, dyslipidemia, body weight gain, orthostatic hypotension, leukopenia, neutropenia, agranulocytosis, seizures, cognitive motor impairment, suicide, and suicidal ideation.205
Pediatric patients (n = 920), aged 6 to 17 years, being treated with aripiprazole for schizophrenia, bipolar mania, or autistic disorder were included in clinical trials that assessed safety.205 Of these patients, 117 were treated for at least 1 year and 465 were treated for at least 180 days.205 Adverse events reported in these trials with a frequency of more than 10 percent included: somnolence, headache, vomiting, extrapyramidal disorder, fatigue, increased appetite, insomnia, nausea, nasopharyngitis, and weight increased.205
Quetiapine
The harms data provided for quetiapine have been gathered from the package insert and FDA approval documents.206,207 Only FDA review documents for quetiapine immediate release were assessed. Review documents and adverse event data for quetiapine extended release were not included. The only FDA approval document that contained pediatric harms data was the document assessing QTC prolongation.206
Adverse events referenced in the warnings/precautions section of the package insert include: suicidal thoughts and behaviors, neuroleptic malignant syndrome, hyperglycemia, dyslipidemia, weight gain, tardive dyskinesia, hypotension, increased blood pressure, leukopenia, neutropenia and agranulocytosis, cataracts, hypothyroidism, hyperprolactinemia, and cognitive motor impairment.207
Ziprasidone
Ziprasidone is not FDA approved for use in pediatric patients and therefore safety data in this population are not available.208 Since pediatric adverse events were not represented in any FDA approval document for this medication, information from these reviews has not been included.
Divalproex/Valproate
Key Points
- Three small, short-term RCTs (1 fair and 2 poor quality for harms) addressed divalproex and reported harms including sleep changes, irritability and mood changes, gastrointestinal upset, and appetite changes.
Overview
Data on harms of valproate were available from three small RCTs and FDA packaging.
Systematic Reviews
We found no systematic reviews assessing harms of divalproex.
Studies Reporting Harms Data
We rated one 8-week RCT178 as fair quality for harms reporting, and two RCTs184,185 as poor quality. The fair quality RCT compared divalproex and placebo in 27 children with stimulant-resistant aggression and ADHD and either CD or ODD.178 Because divalproex was given as add-on therapy with stimulants, many of the reported adverse effects such as anxiety, nail biting, and appetite suppression were attributed to stimulant use. Trends toward a higher rate of treatment-emergent sadness (divalproex: 3 of 14, 20%; placebo: 0 of 13, 0%; p=0.07) and delayed sleep onset (divalproex: 5 of 14, 36%; placebo: 1 of 13, 8%; p=0.08) were noted but not statistically significant. Table 42 outlines reported harms.
One 7-week RCT of 58 adolescent male patients (age 14-18 years) with conduct disorder compared high (500-1500 mg/day) and low (125 mg/day) doses of divalproex.184,209 The only adverse effects reported were gastrointestinal upset (n = 1) and sleepiness (n = 6) (Table 42). Side effects typically disappeared within 4 weeks. Another 6-week RCT comparing a dose of 750 to 1500 mg/day of valproex with placebo in children with CD or ODD reported increased appetite in four (20%) of the 20 participants (ages 10 to 18 years) (Table 42).185
Package Insert Data
The safety information for divalproex sodium was obtained from the package insert.210 FDA review documents were not available for this medication. Adverse events referenced in the warnings/precautions section of the package insert include: suicidal behavior or ideation, thrombocytopenia, hyperammonemia, hyperammonemic encephalopathy, hypothermia, hepatotoxicity, and pancreatitis.211 It is important to note that there is an increased risk of developing fatal hepatotoxicity in patients less than two years of age.210 Specifically in pediatric clinical trials, consisting of 76 patients aged 10-17 years taking divalproex extended release for mania and 231 patients aged 12 to 17 years taking divalproex extended release for migraine, common adverse events (reported >5% and twice the rate of placebo) included: nausea, upper abdominal pain, somnolence, increased ammonia, gastritis and rash.210
According to the package insert, divalproex safety and tolerability in pediatric patients is similar to what has been observed in adults.210 Therefore, the adverse events reported below were not specified for pediatric patients but are included due to the similarity in pediatric safety response. These events are designated by indication.
The following adverse events were reported 89 patients being treated with divalproex for mania: nausea (22%), somnolence (19%), dizziness (12%), vomiting (12%), accidental injury (11%), asthenia (10%), abdominal pain (9%), dyspepsia (9%), and rash (6%).210 Adverse events occurring at an incidence rate of greater than 1 percent (no more that 5%), in patients taking divalproex included: chest pain, chills, chills and fever, fever, neck pain, neck rigidity, hypertension, hypotension, palpitations, postural hypotension, tachycardia, vasodilation, anorexia, fecal incontinence, flatulence, gastroenteritis, glossitis, periodontal abscess, ecchymosis, edema, peripheral edema, arthralgia, arthrosis, leg cramps, twitching, abnormal dreams, abnormal gait, agitation, ataxia, catatonic reaction, confusion, depression, diplopia, dysarthria, hallucinations, hypertonia, hypokinesia, insomnia, paresthesia, reflexes increased, tardive dyskinesia, thinking abnormalities, vertigo, dyspnea, rhinitis, alopecia, discoid lupus erythematosus, dry skin, furunculosis, maculopapular rash, seborrhea, amblyopia, conjunctivitis, deafness, dry eyes, ear pain, eye pain, tinnitus, dysmenorrhea, dysuria, and urinary incontinence.210
The clinical trials used to gather the following adverse events included patients on other antiepilepsy medications.210 Therefore, it is impossible to clearly state if the following reactions are due to divalproex alone in patients with epilepsy.210
Treatment emergent adverse events reported in 77 patients taking divalproex as adjunctive therapy for the treatment of complex partial seizures included: headache (31%), asthenia (27%), fever (6%), nausea (48%), vomiting (27%), abdominal pain (23%), diarrhea (13%), anorexia (12%), dyspepsia (8%), constipation (5%), somnolence (27%), tremor (25%), dizziness (25%), diplopia (16%), amblyopia/blurred vision (12%), ataxia (8%), nystagmus (8%), emotional lability (6%), thinking abnormal (6%), amnesia (5%), flu syndrome (12%), infection (12%), bronchitis (5%), rhinitis (5%), alopecia (6%), and weight loss (6%).210
In a controlled trial assessing the use of high dose divalproex (n = 131) as monotherapy for the treatment of complex partial seizures the following adverse events were reported: asthenia (21%), nausea (34%), diarrhea (23%), vomiting (23%), abdominal pain (12%), anorexia (11%), dyspepsia (11%), thrombocytopenia (24%), ecchymosis (5%), weight gain (9%), peripheral edema (8%), tremor (57%), somnolence (30%), dizziness (18%), insomnia (15%), nervousness (11%), amnesia (7%), nystagmus (7%), depression (5%), infection (20%), pharyngitis (8%), dyspnea (5%), alopecia (24%), amblyopia/blurred vision (8%), and tinnitus (7%).210
In controlled trials encompassing 358 patients treated with divalproex for complex partial seizures the following adverse events were reported in greater than 1 percent of patients but no more than 5 percent: back pain, chest pain, malaise, tachycardia, hypertension, palpitation, increased appetite, flatulence, hematemesis, eructation, pancreatitis, periodontal abscess, petechia, SGOT increased, SGPT increased, myalgia, twitching, arthralgia, leg cramps, myasthenia, anxiety, confusion, abnormal gait, paresthesia, hypertonia, incoordination, abnormal dreams, personality disorder, sinusitis, cough increased, pneumonia, epistaxis, rash, pruritus, dry skin, taste perversion, abnormal vision, deafness, otitis media, urinary incontinence, vaginitis, dysmenorrhea, amenorrhea, and urinary frequency.210
Stimulants
Key Points
- One short-term RCT of methylphenidate reported sleep delay as a harm while an RCT of mixed amphetamine salts including more than 300 children reported harms including insomnia and anorexia.
Overview
Two short-term (≤ 5 weeks), placebo-controlled RCTs of poor quality for harms reporting addressed the safety of mixed amphetamine salts (Adderall®) in the management of ODD182,197 or methylphenidate for CD.187
Systematic Reviews
We did not identify any systematic reviews addressing harms of these agents.
Summary of Studies Reporting Harms Data
The RCT of methylphenidate in patients with conduct disorder187 did not describe assessment of adverse events, and the specific types of events were not detailed in the results though the study noted that adverse effects occurred in 84 percent of those receiving methylphenidate and in 46 percent of those receiving placebo. The authors also noted that “only a few instances of delayed sleep with medication were severe.”187
In a dose-escalation study of mixed amphetamine salts in 308 6 to 17 year olds with ODD, adverse events were typically considered mild, though five participants in the treatment arm reported six severe events (arthrosis, hyperkinesias, insomnia, nervousness, pharyngitis, and one suicide attempt).182,197 Fourteen participants in the treatment arm withdrew from the study due to decreased appetite or insomnia. Table 43 outlines harms occurring in at least 5 percent of patients. Mean decrease in weight was significantly greater in the treatment arm compared with control (range: 1.1 to 3.3 pounds across dosage groups from baseline to endpoint).
In an analysis of the cardiovascular effects of mixed amphetamine salts in this study, no statistically significant treatment-related effects were noted for the following parameters: systolic blood pressure, diastolic blood pressure, pulse rate, PR interval, QRS duration, QT interval, or QTcB interval. Investigators qualitatively assessed the incidence of clinically relevant change from baseline (Table 44. I). No patient experienced a systolic blood pressure ≥ 150 mmHg, diastolic blood pressure > 100 mm Hg, pulse ≥ 110 bpm, or QTcB interval ≥ 500 msec.182,197
Package Insert Data
Amphetamine-Dextroamphetamine
The safety information for amphetamine-dextroamphetamine was obtained from the package insert.212 The extended release formulation was not assessed in this review. The available FDA review documents did not provide additional harms data in the pediatric population. The long-term effects of amphetamine-dextroamphetamine in the pediatric population have not been well assessed.212
Adverse events referenced in the warnings/precautions section of the package insert include: drug dependence, sudden death in patients with cardiac abnormalities, hypertension, heart rate increase, exacerbation of pre-existing psychotic disorder, mixed/manic episodes in patients with bipolar disorder, hallucinations, delusional thinking, mania, aggression, long-term suppression of growth, seizures, visual disturbances, exacerbation of tics and Tourette's syndrome, and impaired cognitive function.212
The additional adverse reactions reported in the prescribing information did not include a frequency.212 These adverse events included: palpitations, tachycardia, elevation of blood pressure, sudden death, myocardial infarction, psychotic episodes at recommended doses, overstimulation, restlessness, dizziness, insomnia, euphoria, dyskinesia, dysphoria, depression, tremor, headache, exacerbation of motor and phonic tics and Tourette's syndrome, seizures, stroke, dryness of the mouth, unpleasant taste, diarrhea, constipation, other gastrointestinal disturbances, anorexia, weight loss, urticaria, rash, hypersensitivity reactions including angioedema and anaphylaxis, Stevens Johnson Syndrome, toxic epidermal necrolysis, impotence, changes in libido, and cardiomyopathy (associated with chronic use).212
Methylphenidate
The adverse event reports available for methylphenidate were gathered from the package insert.213 The package insert utilized for this review included the immediate release and sustained release tablets.213 FDA review documents for this product were not available for assessment.
Adverse events referenced in the warnings/precautions section of the package insert include: sudden death in children with cardiac abnormalities; hypertension; increased heart rate; aggravated symptoms of anxiety, tension, and agitation; mixed/manic episodes in patients with pre-existing bipolar disorder; hallucinations, delusional thinking, or mania; aggression; long-term suppression of growth; seizures; priapism; peripheral vasculopathy; Raynaud's Phenomenon; and visual disturbance.213
More frequent adverse events occurring in children taking methylphenidate included: loss of appetite, abdominal pain, weight loss during prolonged therapy, insomnia, and tachycardia.213 The exact frequency at which these adverse events occurred was not available.213 Additional adverse events reported include: hypersensitivity (including skin rash, urticaria, fever, arthralgia, exfoliative dermatitis, erythema multiforme with histopathological findings of necrotizing vasculitis, and thrombocytopenic purpura); anorexia; nausea; dizziness; palpitations; headache; dyskinesia; drowsiness; blood pressure and pulse changes, both up and down; angina; cardiac arrhythmia, libido changes, toxic psychosis, and Tourette's syndrome (rare).213 Nervousness and insomnia were also reported but could be controlled by decreasing the dosage of methylphenidate and or not taking the medication in the afternoon or evening.213 Adverse events reported but lack definite causal relationships include: abnormal liver function, ranging from transaminase elevation to hepatic coma; isolated cases of cerebral arteritis and/or occlusion; leukopenia and/or anemia; transient depressed mood; aggressive behavior; scalp hair loss.213 Neuroleptic malignant syndrome (NMS) was also reported but occurred most often in patients taking other medications associated with NMS.213
Nonstimulants
Atomoxetine
Overview
Headache and anorexia were common side effects of treatment in the included studies. In the broader literature on atomoxetine (i.e. broader study populations,) the most common adverse events reported in clinical trials in child and adolescent patients (n = 1597) included: abdominal pain (18%), vomiting (11%), nausea (10%), fatigue (8%), irritability (6%), therapeutic response unexpected (2%), weight decreased (3%), decreased appetite (16%), anorexia (3%), headache (19%), somnolence (11%), dizziness (5%), and rash (2%).214
Systematic Reviews
We did not identify any systematic reviews addressing harms of atomoxetine.
Summary of Studies Reporting Harms Data
Two double blind, randomized clinical trials compared atomoxetine with placebo for management of oppositional defiant disorder.176,179 In both studies, atomoxetine was titrated to a target dose of 1.2 mg/kg/day. One 9-week RCT,176 considered poor quality for harms reporting, included 180 children between the ages of 6 and 17 years diagnosed with ADHD and either ODD (74.4%) or CD (24.4%) randomized to either fast or slow titrated atomoxetine or placebo. Table 45 summarizes treatment emergent harms. Rates of pre-defined clinically relevant adverse effects were higher in both treatment groups compared with placebo (p<0.001), but rates between treatment arms were not significantly different. One serious adverse event related to treatment (stomach cramps and abdominal pain) occurred in the fast titration arm. Eight participants in the active treatment groups (6 in the fast titration group, 2 in the slow titration group) discontinued the study due to adverse events: nausea and vomiting (n = 3), aggression (n = 1), fatigue (n = 1), headache (n = 1), tachycardia (n = 1), suicidal ideation of moderate severity (n = 1). Analyses of the effects of pretreatment use of psychostimulants and treatment emergent harms were not significant.
Another poor quality RCT enrolled children between the ages of 6 and 15 (mean: 9.9) years with ADHD and ODD symptoms.179 Harms reported were generally considered mildly or moderately severe with five (undefined) instances of greater severity. Three children discontinued the study due to adverse events (reasons not defined). Body weight increased slightly in the placebo arm and decreased slightly in the atomoxetine arm (p<0.001) as did mean height (p=0.021). Table 45 outlines other harms reported.
Package Insert Data
The adverse event data from the atomoxetine package insert were gathered from 5382 children or adolescent patients with ADHD participating in clinical trials in which 1625 were treated for longer than 1 year and 2529 were treated for over 6 months.214 The original FDA review document contained extensive documentation of harms data.215 A summary of this data is provided below.215
Adverse events referenced in the warnings/precautions section of the package insert include: suicidal ideation, severe liver injury, cardiovascular events (sudden death, stroke and myocardial infarction), increase in blood pressure and heart rate, orthostasis, syncope, emergent psychotic or manic symptoms, aggressive behavior, hostility, urinary hesitation, urinary retention, and priapism.214
The most common adverse events reported in clinical trials in atomoxetine receiving child and adolescent patients (n = 1597) included: abdominal pain (18%), vomiting (11%), nausea (10%), fatigue (8%), irritability (6%), therapeutic response unexpected (2%), weight decreased (3%), decreased appetite (16%), anorexia (3%), headache (19%), somnolence (11%), dizziness (5%), and rash (2%).214
Post-marketing reports specifically from adolescent patients revealed the following additional adverse events: paraesthesia, urinary hesitation, urinary retention.214 Additional adverse events gathered from post-marketing data representing a combination of adults and children included: QT prolongation, syncope, Raynaud's phenomenon, lethargy, hypoaesthesia, sensory disturbances, tics, depression and depressed mood, anxiety, libido changes, hyperhidrosis, male pelvic pain, and seizures.214 It is important to note that in the patients that reported seizures, existing seizure disorders and additional risk factors for seizures may have been present.214
Infrequent serious adverse events reported in the sponsor's new drug application database included: seizure cases (n = 2), angioedema (n = 1), and elevated liver function test (n = 1).215 An additional serious adverse event was reported in clinical trials: one patient with syncope.215
When compared to methylphenidate, the following adverse events occurred at least twice as frequent in the pediatric atomoxetine group (n = 313): vomiting (13.1%), asthenia (7.0%), allergic reaction (3.5%), sinusitis (3.5%), constipation (3.2%), hostility (3.2%), unexpected benefit (2.9%), abnormal dreams (2.6%), chest pain (2.6%), personality disorder (2.6%), gastrointestinal disorder (1.9%), sleep disorder (1.9%), nausea and vomiting (1.6%), gastroenteritis (1.3%), tooth disorder (1.3%), conjunctivitis (1%), ear disorder (1%), leukopenia (1%), mydriasis (1%), otitis externa (1%), and surgical procedure (1%).215
Guanfacine
Overview
In the one medium size study of guanfacine, somnolence, sedation, and headache were frequently reported treatment emergent adverse events.177 We summarize additional potential adverse events reported in the FDA documentation.
Systematic Reviews
We did not identify any systematic reviews addressing harms of guanfacine.
Summary of Studies Reporting Harms Data
One 9-week, placebo-controlled RCT assessed extended release guanfacine (maximum dose 4 mg/day) in children between the ages of 6 and 12 years diagnosed with ADHD and ODD symptoms.177 Use of concomitant ADHD medication was not allowed and was discontinued at the beginning of the study washout period. Treatment emergent adverse events occurred more frequently in the treatment group versus placebo (n = 114/136, 83.8% in the treatment arm vs. 45/78, 57.7% in placebo) and most were considered mild or moderate (Table 46). Predefined severe harms occurred in 14 children receiving guanfacine and in no children in the placebo group. Fourteen children in the treatment group (none in the placebo arm) also discontinued the study due to adverse events, which included sedation and somnolence. Baseline heart rate decreased by 11.6 beats per minute compared with 1.2 in the placebo arm. Twenty-five children in the guanfacine arm also developed abnormal heart rhythms during treatment. ECG analyses showed some changes from baseline in both groups but changes were not considered clinically significant. While the study noted contacting participants at 30 days post-treatment to assess for continuing harms, no longer term harms data are reported.
Package Insert Data
The safety and efficacy of guanfacine in pediatric patients has been reported in the medication package insert and the initial FDA approval documents.216,217 Adverse events referenced in the warnings/precautions section of the package insert include: dose dependent decrease in blood pressure and heart rate as well as somnolence and sedation.217 Adverse events for guanfacine can be separated by events occurring in patients receiving monotherapy or adjunctive therapy.
Common adverse events occurring in adult and pediatric patients taking guanfacine as monotherapy, at an incidence rate of more than 5 percent, and occurring at least twice as often as placebo included: somnolence, fatigue, nausea, lethargy, and hypotension.217 Adverse events reported in short term clinical trials conducted in pediatric patients diagnosed with ADHD and taking guanfacine at fixed doses (incidence rate of more than 2%) included: somnolence/sedation, headache, fatigue, abdominal pain, dizziness, hypotension, dry mouth, nausea, lethargy, dizziness, irritability, decreased appetite, dry mouth, and constipation.217
Common adverse events occurring in the adult and pediatric patients taking guanfacine as adjunctive therapy, at an incidence rate of 5 percent or higher and occurring at least twice as often as placebo included: somnolence, fatigue, insomnia, dizziness, and abdominal pain.217 Adverse events reported in short term clinical trials conducted in pediatric patients (age 6-17) diagnosed the ADHD and taking guanfacine at fixed doses (incidence ≥2%) included: headache, somnolence, insomnia, fatigue, abdominal pain, dizziness, decreased appetite, nausea, diarrhea, hypotension, affect lability, bradycardia, constipation and dry mouth.217
Adverse events reported in additional clinical trials included: atrioventricular block, sinus arrhythmia, dyspepsia, stomach discomfort, vomiting, asthenia, chest pain, hypersensitivity, increased alanine amino transferase, increased weight, convulsion, agitation, anxiety, depression, nightmare, increased urinary frequency, enuresis, asthma, hypertension, and pallor.217 Additional common adverse event reported in the original FDA approval document for pediatric patients treated with guanfacine included: fatigue (14%), lethargy (6%), somnolence (30%), sedation (10%), headache (23%), dizziness (6%), irritability (6%), insomnia (5%), affective lability (2%), nightmare (2%), upper abdominal pain (10%), nausea (6%), dyspepsia (3%), dry mouth (4%), constipation (3%), hypotension (6%), blood pressure decreased (2%), sunburn (2%), appetite decreased (5%). 216 In addition, 7 percent of patients taking guanfacine experienced hypotension compared to 3 percent of the placebo group.217 Adverse events that were considered dose-related in patients taking guanfacine were hypotension, somnolence, sedation, abdominal pain, dizziness, dry mouth, decreased blood pressure, decreased heart rate, and constipation.216 Based on these adverse events, it is not surprising that upon abrupt discontinuation of guanfacine, pediatric patients experienced transient rebound increases in blood pressure and heart rate.216 Patients in the guanfacine group reported sedative effects more often than placebo (53% and 17% respectively).216 These sedative effects included somnolence, sedation, hypersomnia, fatigue, lethargy, and asthenia.216 Increased psychiatric related adverse events also occurred more often in guanfacine treated patients including: irritability (5%), affective lability (4%), aggression (1.4% vs. 0.7%), agitation (1.4%), depressed mood (0.8%), and anxiety (0.4%).216
In pediatric studies, patients discontinued guanfacine therapy due to (n = 513): hypotension (6), QT interval prolongation (3), bradycardia (1), somnolence (19), sedation (11), fatigue (8), asthenia (1), lethargy (1), dizziness (3), nightmare (1), insomnia (1), and headache (5).216 Prolongation of the QT interval was considered a dose and exposure response relationship, i.e. greater exposure to guanfacine places patients at a greater risk of QT prolongation.216 Specifically it was reported that the QTc interval would increase by 1 millisecond for every unit (ng/mL) increase in serum guanfacine.216
In long term studies (at least 12 months) guanfacine was found to increase patient's weight by an average of 17.2 pounds.216 Serious adverse events in these long-term studies included (n = 446): syncope (7), loss of consciousness possibly due to a syncopal episode (1), orthostatic hypotension (1), seizures (2), accidental medication overdoses (2) and intentional medication overdose (1).216 According to the literature, the rate of syncope in pediatric populations requiring medical attention have been estimated at 126 to 300 per 100,000 per year.216
Post-marketing studies reported that in 21,718 patients taking guanfacine 1 mg/day for 28 days experienced the following adverse events (more than 1% incidence): dry mouth, dizziness, somnolence, fatigue, headache, and nausea.217 Additional adverse events reported less frequently include: edema, malaise, tremor, palpitations, tachycardia, paresthesias, vertigo, blurred vision, arthralgia, leg cramps, leg pain, myalgia, confusion, hallucinations, impotence, dyspnea, alopecia, dermatitis, exfoliative dermatitis, pruritus, rash, and alterations in taste. 217 In addition, syncope was reported in 10 guanfacine treated pediatric patients; which occurred after long exposure to the medication.217 The sponsor provided additional post-marketing data by searching FDA's adverse drug reactions (ADRs) and adverse event reporting system (AERS) for guanfacine related adverse events reported between January 1, 1969 to March 31, 2005.216 This search uncovered 955 adverse events reported for 309 pediatric patients (age <17).216 The most commonly reported adverse events included: somnolence (22 events), drug ineffective (19), aggression (18), fatigue (15), weight increased (15), abnormal behavior (12), tic (12), nausea (11), anger (10), disturbance in attention (10), mania (10), sedation (10), agitation (9), condition aggravated (9), insomnia (9), lethargy (9), vomiting (9), and weight decreased (9). 216 Serious adverse events identified included: death (3), convulsion (18), loss of consciousness (7), depressed level of consciousness (4), stupor (3), cardiac arrest (2), cardiac failure (2), myocardial infarction (2), syncope (3), chest pain (4), aggression (18), abnormal behavior (12), tic (12), attention disturbance (10), mania (10), agitation (9), hostility (8), irritability (7), mood swings (7), psychomotor hyperactivity (7), and movement disorder (3).216
Studies assessing adverse events in children (ages 6-17) with ADHD receiving guanfacine (4 mg/day) in combination with a stimulant medication revealed the following psychiatric adverse events: irritability, anxiety, insomnia, initial insomnia, depression.216 Common adverse events reported in these patients included: fatigue (35%), headache (33%), upper abdominal pain (32%), irritability (23%), somnolence (19%), and insomnia (16%).216
Key Question 6. Do interventions intended to address disruptive behaviors and identified in Key Questions 1-4 vary in effectiveness based on patient characteristics (KQ6a), characteristics of the disorder (KQ6b), treatment history of the patient (KQ6c), or characteristics of the treatment (KQ6d)?
Overview of the Literature for KQ6
We identified 24 studies88,89,98,100-102,104,106,119,120,122,125,126,129,130,134-136,138,140,179,182,187,218 reported in 37 publications88,89,98,100-102,104,106,119,120,122,125,126,129,130,134-136,138,140,156,159,162,163,166,169-172,179,182,187,218-222 that addressed KQ6.
Patient Characteristics (KQ6a)
Psychosocial Interventions
Five studies of preschoolers reported tests for mediation and moderation by patient characteristics. Three of those were in studies of the Incredible Years program, and results were inconsistent.138,158,159 One publication158 reported that single parenthood, low socioeconomic status, and teen parenthood, did not significantly moderate change in ECBI scores over the course of treatment with IY. However, sex, age, and maternal depression were significant moderators with boys in the IY groups having better outcomes compared with girls (effect size: 0.03, p=0.04). Younger children also had better conduct problem outcomes compared with older (effect size: 0.03, p=0.04), and children of depressed mothers in the IY group had improved outcomes compared with children of depressed mothers in the control group (effect size: 0.05, p=0.004). By contrast, a study of the IY parenting intervention,138 also examined the impact of patient characteristics such as child age, sex, risk of poverty, disadvantaged socioeconomic status, and risk factors for conduct disorder (single parent, teenage parent, parental depression, family poverty, parental drug use or criminal history) and did not report similarly significant moderation effects for ECBI outcomes. A third study102 reported that child gender and maternal education were significant effect moderators.159
One study of Triple P in preschoolers tested for mediation and moderation and did not report that any of the examined variables (family risk factors, baseline maternal rated ECBI Intensity) predicted treatment outcome.140,160,162 The study of PCIT in preschoolers testing for mediation by patient characteristics reported that baseline respiratory sinus arrhythmia moderated treatment outcomes.98,156
Four studies of psychosocial interventions for disruptive behaviors in school-age children reported tests for mediation and moderation.
Two studies reported no mediation or moderation of treatment effects for gender134 and child welfare system involvement;89 one study reported significant moderation by neighborhood223 and another reported that in a test nine potential moderator variables on three outcome variables that children of younger mothers appear to have benefitted more but also that this finding could likely just have been by chance given the number of comparisons.122 Finally, one study of the Project Support intervention reports partial mediation of CBCL and ECBI over time within individuals was present for several variables examining characteristics of children's mothers including inconsistency, mother-child psychological aggression, and mother's trauma history. Maternal Global psychiatric symptoms also demonstrated partial mediation and were more strongly related to child outcomes in the Project Support group than in the comparison group.100
Three studies tested for potential mediation and moderation among the group of studies evaluating psychosocial interventions for teenagers with disruptive behaviors.
Two studies indicated potential moderation of treatment effects by family functioning-related variables.106 172 For example, one secondary analysis of data from an RCT comparing MST to treatment as usual reported that families with more adaptive functioning at baseline benefitted more from MST.172 One study reported that MST had greater positive effect among boys than among girls.136
Taken together, there is some evidence that treatment outcomes may vary based on patient characteristics, but results are inconsistent likely due to heterogeneity across individual studies.
Pharmacologic Interventions
No identified studies addressed KQ6a.
Characteristics of the Disorder (KQ6b)
Psychosocial Interventions
Inconsistent results are reported for the potential mediating and moderating impact of baseline severity of child disruptive behaviors for treatment outcomes.102,129,158,159 Personality traits such as difficult temperament in preschoolers102,159 and psychopathy in teenagers120,169 were identified as potential mediators or moderators. The one study that examined the impact of concomitant developmental disabilities in a small subsample of the overall study sample was shown to weaken effectiveness of one intervention in school-age children.88
For studies of preschoolers, post-hoc mediator and moderator analyses in one RCT (reported in 2 publications)129,158 of IY compared with a waitlist control group tested the effects of multiple variables on outcomes and reported that baseline child deviant behaviors did not significantly moderate ECBI scores. Another RCT (also reported in 2 publications)102,159 compared a nurse-led IY intervention, psychologist-led IY, and delivery of the IY book without specific therapist-led intervention to parents assessed multiple potential predictors, mediators, and moderators of outcomes on the CBCL and ECBI. Higher baseline levels of life stress, parent stress, child behavior problems, and parent-child dysfunction were associated with greater improvement on the ECBI Intensity scale and CBCL Externalizing scale, but lower levels of life stress, difficult child temperament, and parent-child dysfunction were associated with greater treatment gains on both measures (p<0.01).
Regarding potential mediation and moderation of treatment effects for school-age children with disruptive behaviors, one study showed that one intervention (PPCP) was more effective for children with behavioral problems (but no developmental delay) than for children with behavioral problems plus developmental delay.88 One publication220 from an RCT101 of school-aged children referred for disruptive behavior and randomized to receive the intervention described above as Modular in a community or outpatient clinic setting examined associations between characteristics of the primary or comorbid disorders at baseline and end of treatment outcomes. Baseline CD was a strong predictor of persistent CD symptoms over time. This suggests that baseline CD is associated with reduced effectiveness, at least for the intervention examined in this study. Similarly, this study looked at specific ODD symptoms and reported that the ODD hurtful dimension, which is described as spiteful or vindictive behaviors, was also associated with reduced intervention effectiveness.
Studies examining potential mediation and moderation of treatment effect that examined interventions for teenagers with disruptive behaviors reported that psychopathy and family characteristics partially mediated / moderated treatment effect. In one study of MST, MST was found to be more effective in decreasing externalizing problems for youth with less psychopathy (defined as callous/unemotional traits, narcissism, and impulsiveness).169 Another study of MST similarly reported that youth scoring lower on a measure of callous/unemotional traits and narcissism benefitted more from MST than did youth scoring higher on each of these measures.120
Pharmacologic Interventions
Comorbid ODD is commonly present in children and adolescents with ADHD, and studies frequently included participants with both. In the two RCTs of atomoxetine and one RCT of guanfacine, inclusion criteria specified children with ODD and comorbid ADHD a priori, based on strict diagnostic criteria.176,177,179,190 For the two RCTs of stimulants; the population included a large proportion (nearly two thirds) of patients with comorbid ADHD182,187 but because results are not provided for participants with and without ADHD, the added or separate effect of ADHD on effectiveness of the treatment cannot be discerned.
Severity of disease at baseline may be an important mediator in treatment response. Baseline SNAP-IV ODD scores ranged from 15.5 (4.4) in one RCT of atomoxetine176 to 17.2 (3.3) in a second RCT of atomoxetine.179 All three RCTs of nonstimulants found significant effects regardless of baseline symptom levels.
One RCT of the stimulant mixed amphetamine salts extended release182 looked at the treatment effect stratified by baseline severity (based on baseline ODD subscale score ≥1.7) in a post hoc reanalysis of the per protocol population. The mean change from baseline in ODD scores on the SNAP-IV ODD parent rating was greater for the high baseline ODD severity group. Of note, the baseline scores were low in almost half of the population of the study.
It is not clear if treatment-related changes in ODD symptoms are independent of changes in ADHD symptoms in this population. One study of atomoxetine176 used a path analysis to evaluate if the treatment effect on ODD symptoms were influenced through the treatment effect on ADHD and/or CD symptoms; they found a nonadditive effect, implying a negative direct effect of atomoxetine on ODD symptoms. In a post hoc analysis of another atomoxetine RCT, authors found that the percent reduction from baseline to endpoint in oppositional symptoms (CPRS-R:L ODD subscale) and ADHD symptoms were highly correlated (r=0.74).
Treatment History (KQ6c)
Psychosocial Interventions
No identified studies addressed KQ6c.
Pharmacologic Interventions
Only one RCT of atomoxetine176 examined the interaction of treatment history defined as prior treatment with a stimulant on study outcomes. Overall, 44 percent of participants had received prior treatment with stimulant medication. In a post hoc analysis, there was a significant interaction (p=0.032) between prior stimulant treatment status and study outcome. Both groups improved over the course of treatment with atomoxetine, but the effect of treatment was greater among the patients with a prior history of stimulant treatment (effect size: 0.860) than for the non-pretreated patients (effect size: 0.165). Replication of this finding in other studies is needed.
Characteristics of the Treatment (KQ6d)
Psychosocial Interventions
Studies of psychosocial interventions for children with disruptive behaviors examining if interventions varied in effectiveness based on characteristics of the treatment primarily evaluated variation based on dose and, for interventions including a parent component either alone or in combination with other components, based on whether changing parenting practices mediated intervention effectiveness.
Four studies examined the potentially moderating impact of dose and reported inconsistent effects.102,104,122,126 One RCT conducted in Norway examined the dose-response relationship by comparing intervention effectiveness for mothers attending at least 75 percent of the scheduled sessions to those who did not and reported more improvement on parent reported outcomes of child disruptive behaviors for mothers who attended more than 75 percent of sessions than those who attend less sessions.126 One RCT conducted in Sweden reported complete mediation of the effect of parent management training on child disruptive behaviors for dose as defined by a measure of the extent to which parents had completed assigned homework.122 One RCT conducted in the United States examined the impact of a cognitive behavioral group therapy for adolescents with depression on comorbid disruptive behaviors, as compared to life skills tutoring. The authors evaluated the impact of dose as defined by group attendance.104 The interaction of group attendance by treatment arm was nonsignificant. One RCT conducted in the United States examined the impact of IY programs led by primary care nurses (group 1) or psychologists (group 2), in comparison to giving parents the IY book but no specific interventionist-led training.102,159 Dose effect analyses suggest that the children of parents who attended more training sessions showed more improvement.159
Eleven studies examined whether the effectiveness of interventions delivering a parent component, alone or in combination with other intervention components, was mediated by changes in parenting practices, confidence, or stress.87,119,120,122,125,129,130,146,158,170,219
Three studies of preschool-age children examined this potential mediator. One prospective cohort study evaluating IY parent training compared with usual care reported that improvement in child conduct problems was mediated by decreased parental use of critical statements.87 One RCT comparing IY to a waitlist control group tested the effects of multiple variables on outcomes,129,158 and reported that intervention status correlated with improvement in positive but (not negative ) parenting behavior, which in turn was itself correlated with improvements on the ECBI (p<0.014). An RCT evaluated an intervention program (Hitkashrut) combining elements of parent training models including parental self-regulation, involvement of fathers, parent-child communication skills, and behavior management compared with undefined minimal intervention.119 Intervention group changes in child conduct problems from baseline to post-treatment were mediated by changes in parenting practices and parent reported stress.119
Four studies of school-age children examined this potential mediator. One study reported that improved positive parenting skills and that reduced harsh and inconsistent parenting partially mediated intervention effectiveness.122 One study reported that reduced harsh and inconsistent parenting skills partially mediated intervention effectiveness, but that improvements in positive parenting skills did not.219 Two studies reported that improved positive parenting skills partially mediated parent reported child disruptive behaviors.125,130,166
Pharmacologic Interventions
No identified studies addressed KQ6d.
- Description of Included Studies
- In children under 18 years of age treated for disruptive behaviors, are any psychosocial interventions more effective for improving short-term and long-term psychosocial outcomes than no treatment or other psychosocial interventions?
- In children under 18 years of age treated for disruptive behaviors, are alpha-agonists, anticonvulsants, beta-blockers, central nervous system stimulants, first-generation antipsychotics, second-generation (atypical) antipsychotics, and selective serotonin reuptake inhibitors more effective for improving short-term and long-term psychosocial outcomes than placebo or other pharmacologic interventions?
- In children under 18 years of age treated for disruptive behaviors, what is the relative effectiveness of any psychosocial interventions compared with the pharmacologic interventions listed in Key Question 2 for improving short-term and long-term psychosocial outcomes?
- In children under 18 years of age treated for disruptive behaviors, are any combined psychosocial and pharmacologic interventions listed in Key Question 2 more effective for improving short-term and long-term psychosocial outcomes than individual interventions?
- What are the harms associated with treating children under 18 years of age for disruptive behaviors with either psychosocial or pharmacologic interventions?
- Do interventions intended to address disruptive behaviors and identified in Key Questions 1-4 vary in effectiveness based on patient characteristics (KQ6a), characteristics of the disorder (KQ6b), treatment history of the patient (KQ6c), or characteristics of the treatment (KQ6d)?
- Findings - Psychosocial and Pharmacologic Interventions for Disruptive Behavior ...Findings - Psychosocial and Pharmacologic Interventions for Disruptive Behavior in Children and Adolescents
- RecName: Full=SURP and G-patch domain-containing protein 1; AltName: Full=RNA-bi...RecName: Full=SURP and G-patch domain-containing protein 1; AltName: Full=RNA-binding protein RBP; AltName: Full=Splicing factor 4gi|61216666|sp|Q8IWZ8.2|SUGP1_HUMANProtein
Your browsing activity is empty.
Activity recording is turned off.
See more...